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 The maintenance of vascular function has emerged as an important factor in 
keeping rates of cardiovascular disease (CVD) low.  Endothelial progenitor cells (EPCs) 
are derived from the bone marrow and have been found to play a role in postnatal 
neovascularization (6) and re-endothelialization (106; 130).  Reduced EPC number and 
function, including colony formation and migration, and increased senescence have been 
associated with death from cardiovascular diseases (133), CVD risk factors (126), future 
coronary events (103), and endothelial dysfunction (51). Oxidative stress has been 
proposed as a mechanism that decreases EPC number and function in vitro. In particular, 
oxidized LDL (OxLDL) has been shown to decrease EPC number and function (132), 
and increase EPC senescence (63) in vitro.  Regular physical activity is related to lower 
rates of CVD; however the mechanisms underlying the benefits of exercise in the 
prevention of CVD are not fully clear.  Exercise may improve the number (77; 77; 78), 
and function (54) of EPCs while improving oxidative stress status (127; 129).   
  
 The primary purpose of this study was to compare endothelial progenitor cell 
(EPC) number, EPC clonogenic capacity, and senescence, in healthy men that have 
participated in greater than 20 years of moderate- to high-intensity exercise with age-
matched control subjects.  To assess the effect of physical inactivity on these markers, a 
subset of exercisers (n=10) stopped exercising for 10 days after which, measures of EPC 
number, colony forming units, and senescence, endothelial function and oxidative stress 
were re-evaluated. 
 Results showed that CD34+/KDR+ cell number, CFU-Hill colonies, and EPC 
senescence were not statistically different between athlete and control groups.   
CD34+/KDR+ cell number was closely related to endothelial function.  Specifically, the 
forearm blood flow response to reactive hyperemia was correlated with CD34+/KDR+ 
number in sedentary participants (AUC1min; r=-0.78, p=0.005).  Additionally, 10 days of 
physical inactivity revealed 5 athletes who either had no change or an increase in 
CD34+/KDR+ number and 5 athletes significantly decreased their CD34+/KDR+ number 
(70 ± 30% vs. -86 ± 7%, p=0.006). In athletes that decreased CD34+/KDR+ number with 
exercise training, the change in EPC number was significantly related to a decline in 
endothelial function (-25.7 ± 15.7% change in peak flow), indicating that regular physical 
activity is important for some athletes to maintain healthy endothelial function, perhaps 
through the maintenance of elevated number of circulating CD34+/KDR+ cells. CFU-Hill 
colony number was strongly correlated with hyperemic blood flow response in control 
participants, such that individuals with better endothelial function had enhanced EPC 
clonogenic capacity (r=0.84, p=0.001). CFU-Hill colony forming capacity was related to 
oxidized LDL independent of physical activity status; however, athletes who participated 
  
in 10-days of exercise detraining demonstrated a trend for a significant decrease in EPC 
senescence (22.8 ± 3.3 before vs. 16.4 ± 3.1% after training cessation, p=0.06), which 
was related to improved total antioxidant capacity (r=-0.66, p=0.04).  Overall, these 
results show that while CD34+/KDR+ number is closely related to endothelial function 
and may be affected by exercise and inactivity, it is not influenced by oxidative stress 
whereas the function of EPCs appears to be affected by oxidative stress and antioxidant 
availability.  These results may contribute to the understanding of the mechanisms 
involved in the maintenance of healthy endothelial function and prevention of 
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Endothelial Progenitor Cells and CVD 
Disruption of endothelial integrity and function occupies a central role in the 
development of atherosclerosis and cardiovascular disease.  Endothelial damage and 
dysfunction are evident prior to the development of atherosclerotic lesions.  Historically, 
it was believed that the growth of new blood vessels and repair of the endothelial layer 
occurred via existing vascular and endothelial cells.  In 1997, Asahara, et al characterized 
a novel group of cells by cell surface antigens (CD34+/Flk-1+) found in circulation that 
differentiated into endothelial cells and were incorporated into sites of angiogenesis (6); 
these new cells were termed endothelial progenitor cells (EPCs). Soon thereafter, Shi, et 
al (106) demonstrated that these cells colonized a graft placed in the canine aorta and 
later, Walter, et al (130) reported that EPCs home, or migrate, to balloon-injured arterial 
segments and re-endothelialize the denuded areas. 
More recently, the factors that stimulate EPC mobilization, homing and 
incorporation have been investigated.  EPCs are released from bone marrow stromal cells 
in response to various stimuli, including vascular endothelial growth factor (VEGF), 
stromal cell-derived factor-1 (SDF-1), erythropoietin (Epo), HMG CoA reductase 
inhibitors (statins), PPARγ agonists, exercise, estrogen, and eNOS (4; 60; 123).  EPCs 
home to sites of vascular injury via signals that include shear stress, (145), VEGF and 
SDF-1 as well as platelets (75), thrombin (116) and apoptotic bodies (58).  The 
mechanisms of incorporation of EPCs into the endothelium are less clear, however, this 




Endothelial progenitor cell number and function have been associated with 
cardiovascular disease, cardiovascular disease risk factors, atherosclerosis progression 
and future occurrence of CVD events (51; 103; 126; 133). In 2001, Vasa, et al (126) were 
the first to report an association between circulating EPC number and EPC functional 
characteristics with coronary artery disease family history and number of atherosclerotic 
risk factors.  They found lower EPC number in patients with a positive family history for 
coronary artery disease (CAD) and impaired EPC migratory response in patients with a 
greater number of atherosclerotic risk factors.  EPC function (assessed by colony-forming 
assay) have also been found to be associated with endothelium-dependent flow-mediated 
vasodilation, a measure of endothelial function (51). This study also found that EPCs 
from patients with a higher risk for cardiovascular events demonstrated greater in vitro β-
galactosidase activity, an indicator of cellular senescence. Interestingly, the number of 
EPCs was found to be a better predictor of vascular reactivity than the Framingham risk 
factor score. More recently, the number of circulating EPCs has been found to 
independently predict atherosclerotic disease progression (103) and cardiovascular events 
including death from cardiovascular causes, revascularization surgery, and hospitalization 
due to cardiovascular events, which included angina, congestive heart failure, stroke, 
myocardial infarction, and arrhythmia (133).   
Cardiovascular disease risk factors such as hypertension and diabetes that are 
related to decreases in endothelial integrity and function have also been associated with 
decreased EPC function. For example, Imanishi, et al (64) reported that EPCs from both 
spontaneously hypertensive rats and human patients with essential hypertension 




increased cell turnover.  Tepper, et al (117) found that EPCs from type II diabetes 
patients had a 48% decrease in proliferation in culture compared to controls.  In addition, 
EPCs from diabetics had decreased adhesion to HUVECS and were 2.5 times less likely 
to participate in tubule formation compared to controls.  These data suggest that patients 
with type II diabetes have impaired EPC function, which may explain the vascular 
complications and increased incidence of peripheral vascular disease, atherosclerosis, and 
cerebrovascular disease in diabetics (17).  Therefore, EPCs appear to be a biological 
marker of endothelial health and function, and EPC dysfunction may lead to an impaired 
vascular and endothelial regenerative capacity, increased atherosclerosis, and CVD. 
 
Endothelial Progenitor Cells and Oxidative Stress 
 Oxidative stress has emerged as an important mechanism in the development of 
endothelial dysfunction, atherosclerosis and progression of CVD.  Sources of reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2) and superoxide anion (O2-) are 
the oxidative burst of immune cells, the electron transport chain and cellular respiration, 
and in the endothelium, the action of the enzymes xanthine oxidase and nitric oxide 
synthase (97). ROS have more recently been recognized as cell signaling factors for 
growth, survival, and apoptosis (67). Oxidative stress occurs with disruptions of the 
redox balance leading to damage to DNA and lipids, and cellular senescence and death. 
 Oxidative stress may be an important factor in the determination of EPC number 
and function.  Although EPCs, similar to other types of stem cells, exhibit higher 
expression of the antioxidant enzymes catalase, glutathione peroxidase and manganese 




have been shown to affect EPC function.  Although Dernbach, et al (25) found that 
inhibition of any one of these enzymes did not increase EPC reactive oxygen species 
(H2O2 and O2-), the inhibition of all three enzymes together increased EPC ROS and 
decreased EPC survival and migration in response to hydrogen peroxide.  In addition, 
Galasso, et al (36) found that mice deficient in GPX-1, the gene that encodes glutathione 
peroxidase, had decreased EPC function, decreased angiogenesis in response to hindlimb 
injury, and increased sensitivity to oxidative stress-inducing peroxide to induce EPC 
apoptosis. Therefore, it appears that EPCs can be vulnerable to ROS when their redox 
status is disrupted by inhibition of their antioxidant enzymes. 
 One consequence of increased oxidative stress is the oxidation of LDL.  In the 
endothelium, LDL oxidation leads to endothelial cell dysfunction, decreased nitric oxide 
(NO) bioavailability, the expression of adhesion molecules on monocytes, and migration 
of monocytes to the subendothelial space.  Therefore, oxidized LDL (OxLDL) is an 
important factor in the pathogenesis of cardiovascular disease.  For example, circulating 
oxidized LDL has been found to be an independent predictor for future cardiovascular 
events in patients with coronary artery disease and diabetes (107; 108).  OxLDL increases 
endothelial dysfunction by decreasing NO bioavailability, increasing proliferation of 
smooth muscle cells, promoting platelet accumulation, and thrombus formation. OxLDL 
also increases damage to the endothelium by impairing the regenerative capacity of 
EPCs.  Recently, ex vivo studies have shown that OxLDL leads to decreased EPC 
number and function and increased senescence.   Wang, et al (132) reported that 
incubation of cultured EPCs with increasing concentrations of oxidized LDL decreased 




manner. Oxidized low-density lipoprotein has been shown to induce EPC senescence, 
decrease telomerase activity and decrease the proliferative capacity of EPCs in vitro via 
increases in oxidative stress (63).  The same group found that in the presence of VEGF, 
OxLDL may contribute to lower EPC function via dephosphorylation of Akt, a protein 
kinase that is activated by growth factors and cytokines (62).  Recently, Ma, et al (82) 
found that OxLDL inhibits EPC survival and impairs their function via inhibition of 
eNOS.  Therefore, the highly-atherogenic OxLDL may directly affect EPCs to further 
decrease endothelial health. 
 
Endothelial Progenitor Cells and Physical Activity 
Regular physical activity is associated with decreased risk of development of 
atherosclerosis and cardiovascular disease and improvement in cardiovascular disease 
risk factors. In addition, physical activity is associated with improved endothelial health 
and vascular function and has been shown to be an effective therapy to improve vascular 
collateralization in patients with coronary artery disease (43).  In general, exercise, both 
acute and exercise training, has been found to stimulate increases in circulating EPCs in 
healthy subjects and patients with ischemic coronary artery disease and cardiovascular 
disease risk, although there are few studies that lend insight into the mechanisms and 
signaling that connect exercise with EPC release and action.  
Exercise training has been shown to increase EPC number and function in mice, 
healthy humans, and some patient populations. In 2004 Laufs, et al (78) showed that 3 
weeks of voluntary wheel running in mice and 4 weeks of exercise training (60-80% peak 




7 days of exercise and EPC number in humans increased 78 ± 34% compared to before 
exercise training.  In this study, both mice and humans had decreased EPC apoptosis 
following exercise.  Steiner, et al (111) demonstrated that 12 weeks of exercise training 
for patients with asymptomatic coronary artery disease (CAD) and/or cardiovascular 
disease risk factors resulted in a 2.9 ± 0.4-fold increase in circulating EPCs, which was 
correlated with an increase in endothelial function.  Exercise training (4 weeks) has also 
been shown to increase EPC incorporation into vascular networks (98).    
In healthy moderately-trained subjects, an acute bout of moderate to hard-
intensity endurance exercise has also been shown to increase EPC number, EPC 
migration and colony-forming units (77). In this study, researchers found that moderate 
(~68% VO2max) and intense (~82% VO2max) running for 30 minutes increased EPC 
number to 235 ± 93% and 263 ± 106%, respectively, but moderate, short term running 
(10 minutes) did not significantly increase EPC number following exercise.  In this study, 
researchers also characterized the time course of EPC number and function in response to 
an acute bout of intense exercise.  Following exercise, EPC number was increased at 10 
minutes to a maximum at 30 minutes then decreased to pre-exercise levels by 24 hours.  
Intensive running increased EPC migration in a similar fashion.  Colony-forming units 
increased as soon as 10 minutes following exercise and remained significantly elevated 
up to 6 hours following exercise.  These data demonstrate that there appears to be both an 
acute exercise and exercise training effect with regard to EPC number and function.  
What remains unknown is the effect of long-term endurance exercise training 




In conclusion, recent data have shown that endothelial progenitor cells serve as a 
source of cells for the regeneration and repair of the vascular endothelium. Decreases in 
EPC number and function are associated with CVD and CVD-related conditions and risk 
factors.  Oxidative stress and OxLDL may not only damage endothelial cells, leading to 
endothelial dysfunction and atherosclerosis progression, but may also damage EPC 
antioxidant capacity, decrease EPC telomere length, telomerase, and viability, thereby 
damaging a source of endothelial regeneration.  However, evidence supporting the 
interaction of OxLDL and EPCs is limited to in vitro studies on cultured EPCs.  Physical 
activity has been shown to increase EPC number both following an acute bout of exercise 
























PURPOSE OF THE STUDY 
 
 
 Endothelial dysfunction has been shown to be one of the earliest events in the 
development of atherosclerosis.  Therefore, maintenance of a functional endothelial layer 
has emerged as an important factor in the prevention of cardiovascular disease.  
Circulating endothelial progenitor cells from the bone marrow have been shown to play a 
role in the repair of the endothelium, however their efficacy may be influenced by 
oxidative stress. 
 Regular physical activity is related to lower rates of cardiovascular disease.   
Exercise training has been demonstrated to improve endothelial function; however, the 
mechanisms of this adaptation are not clear.  Exercise may improve the mobilization of 
circulating endothelial progenitor cells and preserve their function by decreasing the 
influence of oxidative stress. 
  Therefore, the purpose of this study was to 1) evaluate differences in endothelial 
function and EPC number and function between low-active individuals and those with a 
long-term physical activity history, 2) to evaluate the relationship between EPC number 
and function and oxidative stress in these two groups, and 3) to analyze the effects of 10 
days of training cessation in long-term exercisers on EPC number, function, and 












 The central hypothesis of this study is that healthy individuals with chronic long-
term endurance physical activity will have better endothelial function and greater EPC 
number, colony-forming capacity, and decreased EPC senescence and that these factors 




 Long-term physical activity is associated with improved endothelial function 
which is related to greater EPC number, EPC-Colony Forming Units (CFU-Hill), and 
lower EPC senescence compared to age and BMI-matched healthy low-active control 
individuals.   
Specific Aims 
1.1 Determine whether long-term exercisers have greater peak forearm 
blood flow, total hyperemic forearm blood flow, and NOx compared to low-
active control subjects. 
1.2 Determine whether long-term exercisers have greater EPC number, 
greater CFU-Hill count, and lower EPC senescence compared to low-active 
control subjects. 
1.3 Determine whether greater EPC number and CFU-Hill count and 
decreased EPC senescence are related to increased peak forearm blood flow, 






 Oxidative stress is lower in long-term exercisers compared to controls and is 
associated with greater EPC number and CFU-Hill count and lower EPC senescence. 
Specific Aims 
2.1 Determine whether long-term exercisers have lower oxidized LDL and 
higher total antioxidant capacity compared to low-active control subjects. 
2.1 Determine whether greater EPC number and CFU-Hill count and 




 EPC number and CFU-Hill count will decrease and EPC senescence will increase 
following 10-days of training cessation and these changes will be associated with 
decreased endothelial function and increased oxidative stress. 
Specific Aims 
2.1 Determine whether EPC number and CFU-Hill count decrease and EPC 
senescence increases after 10 days of training cessation. 
2.1 Determine whether changes in EPC number, CFU-Hill and EPC 
senescence are related to changes in oxidized LDL, total antioxidant 








 Twelve healthy male long-term exercisers (athletes) aged 55 to 80 years old with 
a training history of at least 20 years were recruited for this study. Athletes had to 
participate in moderate to intense endurance exercise greater than 3 days/week.  Healthy 
low-active male age- and BMI-matched participants (n=11) were recruited as controls. 
Control subjects could not be participating in or have a recent history of moderate to 
intense regular endurance exercise.  Participants were screened over the phone and asked 
to fill out health history and physical activity history questionnaires.  All participants 
were non-smokers, non-diabetic and free of cardiovascular, lung, liver disease, and 
cancer.  Participants did not qualify if they were taking medications that have been 
demonstrated to affect EPC number and/or function.  Briefly, these include HMG-CoA 
reductase inhibitors (statins), angiotensin II receptor antagonists, ACE inhibitors, 
peroxisome proliferator-activated receptor gamma agonists, and EPO.   
 
Testing Procedures 
 Written informed consent was obtained for all subjects and the study was 
approved by the University of Maryland College Park Institutional Review Board. 
 All participants engaged in at least two laboratory visits; 1) a preliminary 
screening visit to evaluate resting blood pressure and fasting blood chemistry profile, and 
to rule out the presence of cardiovascular disease and 2) a second visit to assess 




Athletes who agreed to undergo training cessation for 10 days, returned to the laboratory 
for a third visit after the 10 days for repeated measures of endothelial function, blood-
derived parameters, and body composition.  Athletes were instructed to maintain a stable 
weight for the 10 days of training cessation.  To accomplish this, athletes were given a 
weight data log and instructed to weigh themselves in the morning and evening and 
record their weight in the log. 
 For visits 1 and 2, data collection occurred 24-hours following the athletes’ last 
exercise session.  For all visits, participants were tested following an overnight (12-14 
hour) fast in which they refrained from alcohol and caffeine for at least 24 hours prior to 
the test and any vitamins or medications (antihistamines, NSAIDs, etc) 48 hours prior to 
the test.  As plasma nitrate/nitrite concentration has been shown to be highly influenced 
by dietary nitrate/nitrite intake, and nitrite is an intrinsic vasodilator (76), prior to visit 2 
and 3 for athletes, participants were asked to adhere to a low-nitrate diet for the 3 days 
prior to testing for forearm blood flow and NOx measures. Participants were educated 
about foods/fluids high in nitrates and given a list of foods/fluids to avoid as well as 
samples of low-nitrate meals.  Participants were instructed to record their intake for the 
three days on a log supplied to them.  
 
Maximum Oxygen Uptake (VO2max)   
 VO2max testing was performed on a treadmill with physician monitoring.  Heart 
rate, ECG, and blood pressure were monitored continuously throughout the test. For 




which consisted of the first two 3 minute stages of the Bruce Protocol (1.7 mph, 10% 
grade and 2.5mph, 12% grade, respectively), followed by 2 minute incremental stages 
after which the treadmill grade was increased by 2% until the subject reached exhaustion.  
Treadmill speed for stages three to maximal were determined by the investigator based 
on subject experience, typical run speed, and heart rate such that VO2max was achieved 
between 8-12 minutes.  For low-active participants, the treadmill protocol consisted of 2 
minute stages in which the treadmill was elevated by 2% each stage.  Similar to the 
exercisers, treadmill speed was determined by the investigator based on subject 
experience, typical walking speed, and heart rate such that VO2max was achieved between 
8-12 minutes.  Expired air was sampled using indirect calorimetry.  Briefly, data were 
collected with an online computer system (Oxycon Pro, Viasys) in the mixing chamber 
mode.  Expired volume was recorded via a digital volume transducer and expired gas 
concentrations were analyzed by O2 and CO2 analyzers. Frequency of sample analysis 
was 30 seconds for VO2 and respiratory exchange ratio (RER).  For all tests, three of four 
criteria were met for a valid VO2max test: RER ≥ 1.15, maximal heart rate (age-predicted) 
was reached, a plateau in the VO2max increase with an increase in work rate (< 250mL 
VO2max increase) was observed, or the subject indicated exhaustion. 
 
Endothelial-Dependent Flow-Mediated Dilation 
 Endothelial-dependent dilation was measured via forearm blood flow (FBF, 
ml·min-1·100ml-1 tissue volume) in the non-dominant arm using strain gauge 




supine rest in a quiet, dim, temperature-controlled room (22-25ºC), the subject was 
instrumented with a small wrist pressure cuff, an upper arm pressure cuff on the non-
dominant arm, and a standard automated blood pressure cuff on the opposite side.  A 
mercury-filled strain gauge was fitted to the subject’s forearm which was positioned at an 
angle slightly above the atrium and connected to the Hokanson EC 5R plethysmograph 
(Hokanson Inc.) and chart recorder.    For the baseline measurement, the wrist cuff was 
inflated to 200mmHg to eliminate any artifact from hand blood flow.  The forearm cuff 
was inflated via a rapid cuff inflator (Hokanson E20) to 55mmHg for 7 seconds then 
released for 8 seconds.  Baseline FBF was determined as the average of 3 resting 
measures.   
 For the reactive hyperemic measurement, a baseline blood pressure was recorded 
to determine the inflation pressure in the occlusion cuff (50mmHg above resting systolic 
blood pressure). Forearm ischemia was achieved by a 5 minute occlusion with the upper 
arm pressure cuff.  Following forearm ischemia, forearm blood flow was measured as 
described above (every 15 seconds) continuously for 3 minutes.   
 Reactive hyperemic measures included peak FBF, minimum forearm vascular 
resistance (FVR, mmHg·ml-1·min-1·100ml-1), and duration of hyperemia which was 
calculated as the time (seconds) between cuff release and the return of FBF to +5% of 
baseline.  Area under the FBF curve (AUC, ml/100ml) was calculated according to the 
trapezoidal rule as the area from release of the cuff to the end of the 3 minutes of 
recovery.   Since the maximal hyperemic response has been demonstrated to occur within 




response (AUC1min, ml/100ml) was also calculated.  Flow debt (ml/100ml, baseline FBF 
x duration of occlusion) excess flow (ml/100ml, AUC – (baseline FBF x duration of 
hyperemia) and hyperemic repayment (%, flow debt/excess flow) were also calculated to 
characterize the hyperemic response. 
 
Nitrate/Nitrite (NOx) Assay 
 Plasma was filtered via centrifugation with 10 kD cut-off centrifugal ultrafilters 
(Millipore Corporation) at 9,000g and 4°C for 50 minutes.  Nitrate and nitrite 
concentration (NOx) of the filtered plasma was analyzed using a colorimetric assay 
modification of the Griess reaction as described elsewhere (34).  Briefly, to convert 
plasma nitrate to nitrite, 40µL of filtered sample was incubated with 20µL nitrate 
reductase solution (1050U/L) and 10µL NADPH (175 µM) for 60 minutes.  To remove 
excess NADPH, samples were incubated for 60 minutes in 20µL NH4Cl (250U/L), 10µL 
glutamate dehydrogenase, and 20µL α-ketogluterate (10mM).  The Griess reaction was 
started with the addition of 40µL of sulfanilamide solution (1.0% sulfanilamide in 5.0% 
phosphoric acid) followed by 30 minutes of incubation.  Finally, 40µL of N-1-
napthyethylenediamine dihydrochloride solution (0.1%) was added and samples were 
incubated for 30 minutes.  All incubations occurred at room temperature with the samples 
protected from light.  Absorbance was read at 541nm by a microplate reader (Emax, 
Molecular Devices).  Samples were assayed in duplicate.  The inter-assay and intra-assay 




Circulating Progenitor Cell Number 
 CD34+ (HPC, hematopoietic progenitor cell) and CD34+/KDR+ (EPC) number 
was determined by flow cytometry.  For this assay, 4mL of blood was collected into an 
EDTA-coated tube. Mononuclear cells were separated via density centrifugation (Ficoll-
Paque Plus, GE Healthcare).  Cells were washed twice in PBS and counted with a 
hemocytometer.  1x106 mononuclear cells were immunostained with monoclonal 
antibodies against human CD34 (BD Biosciences) and against human VEGFR2 (R&D 
Systems).  Isotype-identical antibodies (mouse IgG2a-FITC, BD Biosciences, and mouse 
IgG1-PE, R&D Systems) served as controls. For each group of analyses, one set of 
control tubes for machine calibration was generated.  In this case, at least 5x105 cells 
were labeled with CD3-FITC-conjugated mouse anti human mAb (BD Biosciences) and 
5x105 cells were labeled with CD3-R-PE-conjugated mouse anti-human mAb (BD 
Biosciences).  All cells were FcR blocked (Miltenyi Biotech Inc.).  After incubation, cells 
were washed with PBS and fixed in 4% paraformaldehyde. Flow cytometry was 
performed at the University of Maryland School of Medicine Flow Cytometry/Cell 
Sorting CORE Laboratory with a Beckman Coulter Epics Elite ESP flow cytometer and 
cell sorter.   The forward- side-scatter plot was used to identify the lymphocyte gate.  
100,000 events per sample were acquired.  To address reproducibility, in a subset of 
individuals, two samples were analyzed from the same subject (n=30).  The correlation 






Colony Formation Assay (CFU-Hill) 
 The colony forming unit (CFU-Hill) assay is an in vitro assay for the colony-
forming potential of endothelial progenitor cells (51). 14 mL blood was collected directly 
into K3EDTA tubes.  Mononuclear cells were isolated by density gradient centrifugation 
(Ficoll-Paque Plus, GE Healthcare), washed two times with PBS and 2% FBS and 
resuspended in EndoCult® Medium (Stem Cell Technologies).  Cells were counted with a 
hemocytometer and 5 x 106 cells/well were plated on fibronectin-coated 6-well plates 
(BD Pharmingen).  After 48 hours, non-adherent cells were harvested and counted.  1 x 
106 cells/well were re-plated in 4 wells of fibronectin-coated 24-well plates (BD 
Pharmingen).  CFUs were evaluated and counted three days later via inverted light 
microscopy.  A colony was defined as a central core of “round” cells with more elongated 
“sprouting cells” at the periphery.  A central core of cells without cells emanating was not 
counted as a colony.  Colonies were counted manually by individuals trained in the 
identification of colonies.  To address reproducibility, colonies were counted by two 
independent observers.  The correlation between observers was r=0.98, p < 0.001.  The 
endothelial lineage of these cells has been confirmed previously via immunocytochemical 








Endothelial Progenitor Cell Senescence 
  EPC senescence was determined using β-galactosidase Cellular Senescence 
Assay Kit (#KAA002, Chemicon International).  β-galactosidase is a marker expressed 
by senescent but not pre-senescent cells at a pH of 6 and has been used to quantify EPC 
senescence by Hill, et al (21).  For this assay, cultures from the colony-forming assay 
(CFU-Hill) were used.  On day 5 of the EPC-CFU culture following colony counting, 
EndoCult® Medium was changed and cells were incubated for another 48 hours. 
Following 7 days of culture, culture medium was removed and EPCs were washed in 
phosphate-buffered saline (PBS). Cells were incubated in fixation solution for 15 minutes 
(room temperature).  Fixation solution was removed, cells were washed, and senescence-
associated β-Gal stain solution (SA-β-gal) was added to the wells.  Cells were incubated 
protected from light for 4h at 37ºC (no CO2). Cells distant from central colonies from 4 
randomly selected fields that contained 100-200 cells each were analyzed with an 
inverted light microscope (VistaVision, VWR). Cells with a distinctly blue cytoplasm 
were counted as senescent (β-gal-positive).   Total cell number and number of senescent-
positive cells in each field were counted twice.  If counts were >10% different from one 
another, a third count was performed.  Total cell count and number of senescent-positive 
cells were each averaged.  Senescence was quantified by the percentage of β-gal-positive 






Plasma Oxidized LDL 
 Plasma was obtained from blood that was drawn from each subject directly into a 
K3EDTA tube.  Plasma oxidized LDL levels (OxLDL) were measured using a 
commercially-available competitive ELISA kit (Mercodia, Uppsala, Sweden) that utilizes 
the murine monoclonal antibody mAb-4E6.  This technique was developed by Holvoet, et 
al (55) and has been used to relate OxLDL levels with subclinical atherosclerosis (61) 
and coronary artery disease (56).  Briefly, OxLDL in the sample competes with well-
bound OxLDL for biotin-labeled antibody (mouse monocolonal anti-oxidized LDL).  
Biotin-labeled antibody is detected with HRP-conjugated streptavidin and the bound 
conjugate is determined by a reaction with 3, 3’, 5, 5’-tetramethylbenzidine (TMB).  The 
addition of a stop solution (0.5M H2SO4) yields a colorimetric endpoint.  The plate was 
read with a plate reader (Emax, Molecular Devices).  All samples were assayed in 
duplicate.  Two-level control samples (Mercodia Oxidized LDL Control Kit) were 
assayed to confirm assay performance.  These controls were within the manufacturer’s 
specified range. All samples, including controls, were analyzed in a single assay to 
eliminate inter-assay variability.  The intra-assay coefficient of variation was 6.8%. 
 
Total Antioxidant Capacity 
  Total antioxidant activity (aqueous and lipid-soluble antioxidants, including 
vitamins, proteins, lipids, glutathione, and uric acid) in plasma was analyzed via a 




Briefly, this assay measures the ability of antioxidants in the sample to prevent the 
oxidation of ABTS (2,2’-Azino-di-[3-ethylbenzthiazoline sulphonate]) to ABTS •+, a 
radical cation, by metmyoglobin.  ABTS •+ is a green chromogen which was analyzed 
with spectrophotometry at 750nm.  This reaction was compared to that of the control 
antioxidant, Trolox, a water-soluble vitamin E analog.  Samples were assayed in 
duplicate.  All samples were analyzed in a single assay to eliminate inter-assay 
variability.  The intra-assay coefficient of variation was 4.1%. 
 
Body Composition 
 Height and weight were recorded and body mass index, BMI (kg/m2) was 
calculated for all subjects.  To quantify percentages of lean and fat mass, body 
composition was assessed via dual energy x-ray absorptiometry (Hologic, Discovery A, 
software version 12.7.1).  Scanner calibration was performed daily with the 
manufacturer’s quality assurance standard.  Those long-time exercisers who choose to 
stop exercise training underwent a second DEXA scan following the 10 days of training 
cessation. 
 
Framingham Risk Score 
 Hill, et al (51) reported a strong correlation between endothelial progenitor colony 




scores for CHD were calculated based on equations from the Framingham study (136).  
Points were assigned according to age, LDL cholesterol, HDL cholesterol, blood 
pressure, diabetes and smoking status.  10-year heart disease risk was also assigned 
according to the total point value. 
  
Statistical Analysis 
 Analyses were performed with SAS version 9.1.  Data were analyzed for 
normality and heterogeneity of variance.  Student’s t-tests were used to test for 
differences between athletes and control groups.  Where data were found to not meet the 
assumption of normality, the nonparametric Mann-Whitney U-test (Wilcoxon rank sum 
test) was used to compare difference between groups.  In these cases, for descriptive data 
the median (lowest value-highest value) are displayed; for EPC data, means ± SE are 
displayed.  Paired t-tests were used to test for differences between athletes before and 
after detraining. Where paired data were found to not meet the assumption of normality, 
the nonparametric Wilcoxon signed rank test was used to compare athletes before and 
after detraining.  Differences between groups for reactive hyperemic FBF response were 
tested using a repeated measures analysis of variance (ANOVA).  Pearson correlation 
coefficients were used to examine the relationships between normally-distributed 
variables.  For parameters with non-normal distributions, nonparametric Spearman 
correlation coefficients were used. Regression analysis was used to determine the best 
predictors of CD34+/KDR+ endothelial progenitor cells, CFU-Hill colony number, and 




appropriate.   For directional hypotheses, 1-sided p-values are reported and noted when 
used.  All other p-values are two-sided.  An α-level of 0.05 was used to indicate statistical 










 Twelve long-term exercisers and 11 low-active control males participated in the 
study.  Groups were matched for age (62 ± 2 vs. 64 ± 2 years, p = 0.23) and BMI (22 ± 
0.8 vs. 23.5 ± 0.6, p = 0.15).  The percentage of body fat and diastolic blood pressure for 
the low-active group was significantly greater (Table 1, p = 0.02, and p = 0.04, 
respectively) compared to the athletes.  Likewise, long-term exercisers had better blood 
chemistry profiles (Table 1). Although the Framingham risk score was not significantly 
different between groups, there was a significant difference between the groups for 10-
year risk for developing CHD (p = 0.007).  As expected, athletes had a higher VO2max 
compared to low-active controls.  Physical activity questionnaire data revealed that this 
group of athletes, composed of 11 runners and 1 triathlete, exercised an average of 5 ± 
0.4 days a week and had been exercising continuously for 32 ± 3 years.  Low-active 
control participants were not engaging in regular endurance exercise, nor did they have a 
recent history of physical activity.  Low-active participants did engage in activities of 
daily living, such as walking, climbing stairs and gardening, however, these activities 
were neither regular nor intense. 
 Ten athletes agreed to participate in 10-days of training cessation.  Participants 
were instructed to not engage in regular exercise training sessions during this period.  
Activities of daily living (i.e. walking, climbing stairs) were permitted provided the 




weight during the interval.  Therefore, each maintained a body weight log in which they 
recorded their body weights in the morning and evening.  Body weight and BMI did not 
change following training cessation (67.2 ± 2.3 vs. 67.6 ± 2.3 kg and 22.0 ± 0.7 vs. 22.1 ± 
0.7 kg/m2, respectively), however body fat (%) was slightly greater (17.3 ± 1.2 vs. 18.1 ± 
1.1, p<0.001) and SBP was slightly lower (121 ± 4 vs. 114 ± 3, p=0.006) following the 
10 days of training cessation. 
Table 1. Descriptive data 
  Athletes Control p-value 
Variable  (n=12) (n=11)  
Characteristic     
 Age (yr) 62 ± 2 64 ± 2 0.23 
 Height (m) 1.78 ± 0.03 1.76 ± 0.02 0.55 
 Weight (kg) 70.1 ± 2.9 73.0 ± 2.4 0.45 
 BMI 22.0 ± 0.8 23.5 ± 0.6 0.15 
 Body Fat (%) 18.0 ± 1.3 23.5 ± 1.8 0.02 
 SBP (mmHg) 122 ± 3 129 ± 3 0.17 
 DBP (mmHg) 79 ± 2 85 ± 2 0.04 
Blood Chemistry     
 Glucose (mg/dl) 94.5 (83-104) 99 (91-122) 0.09 
 Cholesterol (mg/dl) 199.1 ± 8.9 194.2 ± 10.6 0.72 
 Triglycerides (mg/dl) 66.2 ± 8.4 103.0 ± 13.5 0.03 
 HDL-C (mg/dl) 71.2 ± 3.3 51.0 ± 4.6 0.002 
 LDL-C (mg/dl) 114.8 ± 8.4 122.5 ± 11.4 0.59 








10-year CHD risk (%) 
2.9 ± 0.2 
 
4.0 (0-7) 
7.67 ± 0.86 
4.2 ± 0.5 
 
7.0 (1-9) 





Physical Activity     
 VO2max (ml/kg) 50.0 ± 1.9 28.1± 1.7 <0.0001 
 VO2max (L/min) 3.51 ± 0.17 2.07 0.12 <0.0001 
 
 days/week running 5 ± 0.4   
 miles/week running 36 ± 3   
 years exercising 32 ± 3   
Values are means ± SE. For data that were not normally distributed, median (lowest value-highest 
value) is displayed and p value represents a Mann-Whitney U-test; n, number of subjects; BMI, 
body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; TC, total 





 Table 2 displays the results from resting and reactive hyperemia blood flow 
responses in athletes, athletes who detrained and controls.  Resting forearm blood flow 
ranged from 0.95 to 3.23 ml·min-1·100ml-1 tissue in the total group and was not different 
between athletes and controls.   Following 5 minutes of cuff occlusion, forearm blood 
flow increased in the athlete (p < 0.001) and control (p < 0.001) groups (837.6 ± 90.1 % 
and 608.9 ± 73.6 %, respectively).  Peak forearm blood flow was significantly greater in 
athletes compared to controls (p = 0.03) which corresponded to a lower minimum FVR in 
athletes (p = 0.03).  Athletes also had a shorter hyperemic duration (p = 0.04).  Area 
under the curve for the first minute (AUC1min) was calculated as it has been shown that 
the greatest hyperemic response occurs within the first minute following cuff occlusion 
(21).  This parameter displayed a trend to be lower in controls compared to athletes (p = 
0.08).   
 There were no significant differences in baseline or reactive hyperemic blood 
flow parameters between the 12 athletes at baseline and the 10 athletes who underwent 
detraining.  Following 10 days of training cessation, there were no significant changes in 
any of the forearm blood flow measures. Although peak forearm blood flow and 
minimum forearm vascular resistance remained significantly higher than controls (Table 
2), there was a downward shift in the reactive hyperemic response to the 5-minute cuff 






Table 2. Summary of reactive hyperemic forearm blood flow response. 
Resting Athletes Controls 
FBF (ml·min-1·100ml-1 tissue)   
                               before 
                               after 
      FVR (mmHg·ml-1·min-1·100ml-1) 
                               before 
                               after 
2.23 ± 0.23 (2.26± 0.22) 
2.00 ± 0.28 
 
45.48 ± 5.67 (42.11 ± 4.4) 
51.5 ± 7.2 
2.01 ± 0.20 
 
 
50.8 ± 5.42 
Reactive Hyperemia   
    Peak FBF (ml·min-1·100ml-1)   
                              before 20.4 ± 2.7 (21.7 ± 3.1) 13.2 ± 1.0a,b 
                              after 19.1 ± 1.6  
    % Change in FBF   
                              before 837.6 ± 90.1 (864.0 ± 100.5) 608.9 ± 73.6b 
                              after 1003.4 ± 167.6  
    Minimum FVR  
    (mmHg·ml-1·min-1·100ml-1) 
  
                              before 5.3 ± 0.7 (5.0 ± 0.8) 7.4 ± 0.6a,b 
                              after 4.9 ± 0.5  
    % Change in FVR   
                             before -88.0 ± 1.4 (-88.2 ± 1.5) -84.4 ± 1.3b 
                             after -89.3 ± 1.2  
    Total AUC (ml/100ml)   
                             before 17.7 ± 2.1 (18.6 ± 2.2) 15.2 ± 1.5 
                             after 16.6 ± 1.9  
    AUC1min (ml/100ml) 
                             before 
                             after 
    Flow debt (ml/100ml) 
 
11.0 ± 1.3 (11.6 ± 1.4) 
10.3 ± 1.0 
 
8.13 ± 0.8 
                             before 11.2 ± 1.1 (11.3 ±1.1) 10.1 ± 1.0 
                             after 10.0 ± 1.4  
    Excess flow (ml/100ml)   
                             before 12.5 ± 1.6 (13.1 ± 1.7) 9.7 ± 1.0 
                             after 11.6 ± 1.2  
    Repayment (%)   
                             before 115.8 ± 12.6 (119.6 ± 14.8) 100.3 ± 8.7 
                             after 124.3 ± 9.96  
    Duration (seconds)   
                             before 137.5 ±  9.2 (142.5 ± 10.3) 165.0 ± 8.1a 
                             after 150.0 ± 9.5  
Data are means ± SE.  Sample sizes for the cross-sectional comparison were athletes (n=12), 
controls (n=11).  Values in parentheses represent mean ± SE for athletes (n=10) who underwent 
detraining.   % change, percent change from resting; FBF, forearm blood flow; FVR, forearm 
vascular resistance; AUC, area under curve; AUC1min, area under curve for the first minute of 
reactive hyperemia.  a, p ≤ 0.05, athletes baseline vs. controls; b, p ≤ 0.05, athletes after 




































Figure 1.  Reactive hyperemic response in athletes before and after training cessation and 
control subjects. Data are means ± SE.  Baseline and Training Cessation represent data for 10 
athletes who underwent 10-days of training cessation.  Sedentary (n=11). *, p<0.05 Baseline vs. 




 There was no difference in plasma nitrate/nitrite concentration (NOx) between 
athlete and control groups (11.88 ± 0.94 vs. 11.99 ± 1.39µmol/L, p = 0.95) or in athletes 














 To determine whether oxidative stress status was related to EPC number and 
colony-forming capacity, plasma oxidized LDL (OxLDL) and total antioxidant capacity 
(TAC) were measured.  There were no differences between athlete and control groups in 
mean plasma OxLDL or in OxLDL ratio.  The control group was found to have greater 
TAC compared with athletes.   
Table 3. Oxidative stress data in athletes and controls. 
Variable Athletes Controls p-value 





61.35 ± 4.66 
 
0.55 ± 0.03 
61.77 ± 3.79 
 




TAC (mmol/L) 2.25 ± 0.05 2.54 ± 0.06 0.002 
Values are means ± SE; athletes n=12, controls n=11. OxLDL, plasma oxidized LDL 
concentration; TAC, plasma total antioxidant capacity. 
 
 Plasma OxLDL and TAC did not change with 10 days of training cessation in 
athletes (baseline vs. detraining; 58.99 ± 4.59 U/L vs. 57.82 ± 3.26 U/L, p=0.63, and 2.25 
± 0.06 vs. 2.21 ± 0.08, p = 0.40, respectively). 
 
Endothelial Progenitor Cells 
 Data for CD34+ and CD34+/KDR+ number were not normally distributed; 
therefore, Mann-Whitney U-tests were used to compare differences between athlete and 




either CD34+ HSCs (Figure 2a) or any of the EPC measures including CD34+/KDR+ cell 
number (Figure 2b), EPC-CFU count (Figure 2c), and EPC senescence percent (Figure 
2d) although means were lower for all of these variables in the control group compared to 


























Figure 2a.  CD34+ (HPC) cells in athlete and control groups.  Values are means ± SE; athletes 






































Figure 2b.  CD34+/KDR+ cells in athlete and control groups.  Values are means ± SE; athletes 






















Figure 2c.  Number of CFU-Hill colonies in athlete and control groups. Values are means ± 


























Figure 2d.  Percentage of EPC senescence in athlete and control groups. Values are means ± 
SE; athletes n=12, controls n=11. 
 
 
  Table 4. Circulating progenitor cell data 
 Athletes Control p-value 
Variable (n=12) (n=11)  
CD34+ cells/100,000 events 
 
447 ± 143 342 ± 140 0.22 
CD34+/KDR+ cells/100,000 events 99 ± 39 
 
43 ± 14 
 
0.23 
CFU-Hill (count) 18 ± 4 14 ± 4 0.26 
    
EPC Senescence (%) 23.4 ± 3.7 22.6 ± 5.1 0.45 
Values are means ± SE; n, number of subjects; CFU, colony-forming unit; EPC, Endothelial 
Progenitor Cell. Because data for CD34+ number, CD34+/KDR+ cell number was not normally 
distributed, a Mann-Whitney U-test was used to assess differences between groups and exact test 





 There was considerable individual variability in the response to training cessation 
(Figures 3a-d).  Following 10 days of training cessation, athletes had a significant 
decrease in the number of CD34+ cells (Table 5, p = 0.02).  Although the other EPC-
related variables did not approach statistical significance, the number of CD34+/KDR+ 
cells/100,000 events (p = 0.11), CFU-Hill count (p = 0.17), and EPC-senescence (p = 
0.06) tended to decrease with training cessation.  Following detraining, the athletes had 
an average of 16 ± 7 CD34+/KDR+ cells, which was lower compared to the sedentary 


























































Figure 3a.  CD34+ cells before and after 10-days of training cessation.  Data represent 




































Figure 3b.  CD34+/KDR+cells before and after 10-days of training cessation.  Because 
data for CD34+/KDR+ cell number was not normally distributed, data was analyzed via the 
nonparametric Wilcoxon signed rank test.  Data represent individual responses to training 



























Figure 3c.  Number of CFU-Hill colonies before and after 10-days of training 
cessation. Data represent individual responses to training cessation and mean ± SE. 




























Figure 3d.  EPC senescence before and after 10-days of training cessation.  Data 

















Table 5. Training cessation and progenitor cell data 
Variable Baseline Training 
Cessation 
p-value 
CD34+ cells/100,000 events 
 
322 ± 91  179 ± 37  0.02 
CD34+/KDR+ cells/100,000 events 89 ± 44 
 
16 ± 7  
 
0.11 
CFU-Hill (count) 18 ± 4 12 ± 4  0.17 
    
EPC Senescence (%) 22.8 ± 3.3 16.4 ± 3.1  0.06 
Values are means ± SE; CFU, colony-forming unit; EPC, Endothelial Progenitor Cell. Because 
data for CD34+/KDR+ cell number was not normally distributed, data was analyzed via the 
nonparametric Wilcoxon signed rank test and exact test results are presented.  1-sided p-values 
are displayed.   
 
 
Response to Cessation of Training 
 Examination of individual results from 10-days of physical inactivity revealed 
five athletes who had decreased CD34+/KDR+ cell number (“responders”), and five 
athletes who showed no change or slightly increased CD34+/KDR+ cell number (“non-
responders”). Overall, percent change in CD34+/KDR+ cell number correlated 
significantly with baseline CD34+/KDR+ cell number  (r = -0.75915, p = 0.01) in the 10 
athletes who detrained.  Compared with non-responders, the responders had greater 
CD34+/KDR+ cell number at baseline (169 ± 3 vs. 9 ± 5 cells/100,000 events, p = 0.008) 
and a greater percentage change in CD34+/KDR+ cell number with detraining (-86 ± 7 vs. 
70 ± 30%, p=0.006) .  There were no differences between these groups in baseline or 
percent change with detraining in CFU-Hill colonies or EPC senescence. 
 The baseline forearm blood flow and response to reactive hyperemia parameters 
were analyzed in the two groups (Figures 4 and 5).  Baseline FBF and peak FBF prior to 




0.02 and p = 0.02, respectively), but not after detraining (Table 6).  Of note, peak flow for 
both responders and non-responders was still significantly greater than peak flow for the 
control group after detraining (p=0.02 for both comparisons), however, AUC1min was not.  
There were no differences between responders and non-responders to detraining in the 
percent change in NOx (15.03 ± 7.42% vs. -4.05 ± 25.21%, p=0.50), OxLDL (3.18 ± 
8.71% vs. -3.575 ± 0.69 %, p = 0.48), or TAC (-4.38 ± 2.93% vs. 0.4784 ± 3.37%, 
p=0.31).  The two groups were analyzed for other cardiovascular factors that may have 
influenced differences in vascular reactivity and CD34+/KDR+ cell number and there 
were no differences between responders and non-responders to detraining in age, blood 

































Figure 4.  Reactive hyperemic blood flow in responders to training cessation.  Data 
are means ± SE.  Baseline and Training Cessation represent data for 5 “responder” 











































Figure 5.  Reactive hyperemic blood flow in non-responders to training cessation.  Data are 
means ± SE.  Baseline and Training Cessation represent data for 5 “non-responder” athletes who 


















Table 6. Forearm blood flow in responders and non-responders with training 
cessation. 
Variable Responders Non-Responders p-value 
Baseline    
     Resting FBF  
     (ml·min-1·100ml-1 tissue) 
2.7 ± 0.2  1.8 ± 0.3  0.02 
    
     Peak FBF  
     (ml·min-1·100ml-1 tissue) 
28.4 ± 4.0 
 
15.0 ± 2.2  
 
0.02 
Training Cessation    
     Resting FBF  
     (ml·min-1·100ml-1 tissue) 
 
2.0 ± 0.4 2.0 ± 0.4 0.96 
     Peak FBF  
     (ml·min-1·100ml-1 tissue) 
19.0 ± 2.2 19.1 ± 2.6 0.99 
    
Change in peak FBF (%) -25.7 ± 15.7 32.1 ± 13.3  0.02 
    
Change in AUC (%) -24.8 ± 16.4 24.1 ± 16.3 0.07 
    
Change in AUC1min (%) -25.6 ± 15.9 32.0 ± 17.2  0.04 
Data are means ± SE.  Sample sizes for the group comparison were “responders” (n=5), “non-
responders” (n=5).  Change (%), percent change from baseline to 10-days of training cessation; 
FBF, forearm blood flow; FVR, forearm vascular resistance; AUC, area under curve; AUC1min, 
area under curve for the first minute of reactive hyperemia.   
 
Endothelial Progenitor Cells and Endothelial Function 
 Correlation analysis was performed on the entire group (athletes and controls, 
n=23) to analyze the relationship between EPC variables (CFU-Hill colonies, 
CD34+/KDR+ cells, and EPC senescence) and forearm blood flow parameters. There 
were no significant correlations found for number of CFU-Hill colonies, number of 
CD34+/KDR+ cells or EPC senescence variables with endothelial function variables in the 
combined groups.  Likewise, there were no significant relationships between EPC 




 The athlete and control groups were also analyzed separately for relationships 
between EPCs and forearm blood flow variables.  The athlete group demonstrated a 
significant relationship between the number of CD34+/KDR+ cells and forearm blood 
flow at rest (Figure 6, r = 0.70, p = 0.01).  There were no other significant relationships 
between CD34+/KDR+ number, CFU-Hill colonies, EPC-senescence and forearm blood 
flow variables or NOx in the athlete group. 
 There were several relationships between EPC variables and forearm blood flow 
parameters in the control group.  CD34+/KDR+ number correlated with AUC1min (Figure 
7, r = -0.78, p = 0.005) and excess flow (r = -0.70, p = 0.02). CFU-Hill colonies 
correlated with the percentage change in FBF (Figure 8, r = 0.84, p = 0.001) and 


























Figure 6. Correlation between CD34+/KDR+ cells and resting forearm blood flow 
(FBF) in athletes. 
n = 12 
r = 0.70053 





































n = 11 
r = -0.78083 
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Figure 8. Correlation between CFU-Hill colonies and the change in forearm blood 











n = 11 
r = 0.83596 




 Changes in EPC variables were analyzed for relationships with changes in 
forearm blood flow parameters with 10-days of detraining in athletes.  The percent 
change in CD34+/KDR+ cells from before to after detraining was significantly correlated 
with the percentage change in area under the forearm blood flow curve (minute 1) in 
response to reactive hyperemia (Figure 9, r = 0.70, p = 0.02).  The change in 
CD34+/KDR+ cells with detraining also displayed a trend for a relationship with the 
percentage change in resting forearm blood flow (r = 0.62, p = 0.06).  The percent change 
in CD34+ cells was related to the percent change in hyperemic duration with detraining (r 




























Figure 9. Correlation between the percentage change in CD34+/KDR+ cells and the 
percentage change in AUC1min in athletes with 10-days of training cessation. 
 
 
n = 10 
r = 0.70400 




Endothelial Progenitor Cells and Oxidative Stress 
 Relationships between EPC and oxidative stress variables (OxLDL and TAC) 
were examined for athlete and control groups separately and combined via correlation 
analysis.  Neither oxidized LDL nor TAC was significantly related to CD34+/KDR+ cells, 
CFU-Hill colonies, or EPC senescence in the entire group.  However, CFU-Hill colony 
number showed a tendency to be correlated with OxLDL (Figure 10, r = -.33, p = 0.12).  
This relationship was not evident when groups were analyzed separately.  None of the 
EPC variables were related to TAC in either athlete or control groups.   
 In athletes who underwent 10-days of exercise cessation, the percentage change in 
EPC senescence was significantly related to the percentage change in TAC from before 
to after detraining (Figure 11, r = 0.66, p = 0.04).  The percent change in CD34+/KDR+ 
cells tended to be related to the percentage change in TAC from before to after detraining 
(r = 0.62, p = 0.06). There were no relationships between changes in EPC variables with 































Figure 10. Correlation between CFU-Hill colony number and Ox-LDL in athlete  
(diamonds) and control (triangles) participants.   
 
n = 23 
r = -0.33202 
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Figure 11. Correlation between the percentage change in EPC senescence and the 




Predictors of Endothelial Progenitor Cell Variables 
 Multiple regression analysis was used to determine the best predictors of 
CD34+/KDR+ number, number of CFU-Hill colonies, and EPC senescence in the entire 
cohort, separately for the athlete and control groups, and for the change with detraining in 
athletes. Variables were transformed to meet the testing assumptions when appropriate 
and noted when used. 
 For the combined groups, as Hill, et al (51) reported, greater number of CFU-Hill 
colonies was related to lower Framingham 10-year CHD risk score (p = 0.02) and risk 
percentage (Figure 12, r = -0.49, p = 0.02).  Regression analysis also revealed a 
n = 10 
r = -0.66479 




relationship between log10CFU-Hill colonies and log10OxLDL (p = 0.03) in both groups 
combined.   
 When the control group was analyzed alone, multiple regression analysis revealed 
significant relationships between log10CD34+/KDR+ number and plasma cholesterol (p = 
0.04) and excess forearm blood flow (p = 0.01).  A strong relationship between OxLDL 
and log10CFU-Hill colonies (p < 0.001) was also found.  There were no significant 
predictors of EPC senescence in the control group.   
 For the athlete group, regression analysis revealed only a relationship between 
log10CD34+/KDR+ cells and resting FBF (p = 0.05). 
 In the multivariate analysis to determine the best model to predict the change in 
EPC parameters with detraining, CD34+/KDR+ number had two independent variables in 
the model; percent change in AUC (p = 0.02) and percentage change in TAC (p = 0.10).  
Additionally, EPC senescence was significantly related to the percentage change in TAC 
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Figure 12. Correlation between CFU-Hill colonies and CHD risk. Spearman’s 
correlation coefficient revealed that number of CFU-Hill colonies were strongly 
















n = 23 
r = -0.48869 





 Regular endurance physical activity is associated with enhanced endothelial 
function which has been related to lower incidence of cardiovascular disease (22; 23; 45; 
46).  Evidence indicates that bone-derived progenitor cells targeted toward the vascular 
endothelium (EPCs) may aid in the maintenance of endothelial integrity via endothelial 
repair. However oxidative stress, which has been implicated in the pathogenesis of CVD, 
has been shown in vitro to impair EPCs (25; 62; 63; 66; 82; 132).  Chronic exercise 
training may improve anti-oxidant capacity and may be one mechanism by which 
exercise improves EPC function.  In the present study, we hypothesized that individuals 
who participated in long-term endurance exercise training would have greater hyperemic 
forearm blood flow response, which would be related to greater number of CD34+/KDR+ 
EPCs and better EPC function (measured by CFU-Hill colony forming capacity and EPC 
senescence) compared to low-active control participants. Additionally, we proposed that 
repetitive bouts of acute exercise were important to protect athletes from deterioration of 
EPC number and function therefore, 10-days of training cessation would lead to 
decreased CD34+/KDR+ cell number and EPC function and that these changes would be 
related to diminished forearm blood flow response to reactive hyperemia and increased 
oxidative stress.  The principal findings of this study were: 1) CD34+/KDR+ cell number, 
CFU-Hill colonies, and EPC senescence were not significantly different between athlete 
and control groups, 2) CD34+/KDR+ cell number was closely related to endothelial 
function in low-active controls subjects and athletes who participated in 10-day cessation 
of training, 3) CFU-Hill colony-forming capacity was related to plasma oxidized LDL 




exercise cessation demonstrated a decrease in EPC senescence, which was related to 
improved antioxidant capacity. 
 
EPCs and Endothelial Function 
 Endothelial dysfunction has emerged as a hallmark of early cardiovascular disease 
(96) and predicts cardiovascular disease progression and future cardiovascular events 
(102).  Improvement in endothelial function with exercise training has been demonstrated 
in the coronary (38; 43) and peripheral vasculature (79) and is associated with an increase 
in eNOS expression, increased phosphorylation of eNOS by Akt (44), and decreased NO 
inactivation by reactive oxygen species (2).  Our data revealed that better endothelial 
function, assessed by the forearm blood flow response to reactive hyperemia, was related 
to increased CFU-Hill colonies and decreased CD34+/KDR+ number in low-active 
controls.  Therefore, healthy endothelial function may occur due to improved EPC 
function despite low EPC number. This effect could be indicative of a shift toward the 
regenerative capacity of EPCs at rest from the liberation of EPCs from the bone marrow 
that has been shown to occur with acute exercise (1; 77).  Our results are similar to those 
reported by Hill, et al (51) who found a relationship between greater EPC function (CFU-
Hill colonies) and better brachial artery reactivity in individuals who had various degrees 
of CHD risk.  Interestingly, with our groups combined, we found an equivalent 
relationship between CFU-Hill colonies and Framingham risk as Hill, et al reported.  The 
lack of an association between CFU-Hill colonies and endothelial function in athletes 





 The long-term exercisers in our study showed superior endothelial function 
compared with low-active controls as expected.  However, athletes who had the highest 
reactive hyperemic FBF response had the greatest number of CD34+/KDR+ cells.  
Furthermore, when these athletes stopped exercising, they had a dramatic decrease in 
reactive hyperemic FBF response.  Therefore, in this group of athletes, the repeated bouts 
of acute exercise appears to be essential to maintain high levels of circulating 
CD34+/KDR+ EPCs and endothelial function.  For the other half of the athletes, both 
CD34+/KDR+ cells and endothelial function were not affected by 10 days of exercise 
cessation, indicating that for this group, the chronic nature of their exercise training led to 
an adaptation of enhanced endothelial function that persisted despite the cessation of 
exercise and may be less dependent upon the presence of circulating CD34+/KDR+ cells.  
Interestingly, Werner, et al (135) recently reported increased coronary endothelial 
function in patients with CAD who had greater CD34+/KDR+.  Through the use of 
training cessation, we were able to show a similar relationship in the peripheral 
vasculature in healthy individuals.  It is important to note that the relationship between 
endothelial function and CD34+/KDR+ cells reported herein was seen without differences 
in plasma NOx, which may indicate that there may be other factors involved. The 
molecular mechanisms involved in EPC regulation and their relationship with endothelial 
function have yet to be elucidated. 
 
EPCs and Exercise Training 
 Previous studies have shown that an acute bout of exercise increases the number 




However, results from studies evaluating resting EPC number following exercise training 
in humans are not consistent; specifically, groups have reported that exercise training 
improves resting CD34+/KDR+ cells in patients with CAD (78) and chronic heart failure 
(99) and CD34+/KDR+/CD133+ cells in patients with CAD and CAD risk factors (111) 
but not in healthy young and older men (118) trained for 8 weeks.  It appears that 
exercise training, either short term (8 weeks) or long term (>30 years in our study), does 
not affect resting CD34+/KDR+ cells in healthy individuals, whereas exercise training 
may increase resting circulating EPCs in individuals with cardiovascular disease and 
therefore, greater endothelial damage.  We also found no difference between our groups 
in resting plasma NOx. Nitric oxide has been implicated as an important factor for the 
release of EPCs from the bone marrow (3; 4; 78).  Steiner, et al (111) demonstrated a 
strong relationship between plasma NOx and change in EPC number with exercise 
training in their patients with CAD and CAD risk factors, however this group did not 
control for nitrate intake prior to testing. Given that we did not see a difference in plasma 
NOx, our lack of a difference in CD34+/KDR+ cells is not surprising.  Therefore, as 
previous data have shown, EPCs may be increased with acute exercise, but in healthy 
individuals, resting EPC number is independent of training status. 
 The number of circulating EPCs likely represents the balance between liberation 
of EPCs from the bone marrow and incorporation at the level of the vessel or 
differentiation.  Laufs, et al (77) demonstrated that CD34+/KDR+ cells increase after 30 
minutes of high intensity running in healthy participants, but returned to resting levels by 
24 hours following exercise.  Our results can be explained with this finding as we 




defined EPCs (CD34+/KDR+) equivalently.  We can speculate that in healthy regularly-
exercising individuals, by 24 hours following exercise, EPCs released from the bone 
marrow with exercise have either been incorporated for endothelial repair, 
neovascularization, or have undergone differentiation. 
 With regard to training cessation, we found that CD34+ cells decreased following 
the 10 days of no exercise.  There is little information regarding resting CD34+ cells and 
exercise; specifically, these myeloid cells have been found to be both higher at rest in 
middle-aged runners compared to sedentary controls (13) and no different in older trained 
men compared to older untrained men (118).  To our knowledge, this is the first report of 
a decrease in these cells in long-term trained runners with cessation of exercise.  As bone-
marrow derived hematopoietic progenitors, these cells have the capacity to differentiate 
into endothelial marker-expressing cells that may contribute to angiogenesis (6), have 
been shown to be mobilized after acute myocardial infarction (109), and are also 
emerging as a potential therapy for CAD (71).  Our data reveal that regular bouts of 
exercise are necessary to maintain heightened levels of CD34+ progenitors, which have 
the potential to differentiate toward the vascular endothelium to participate in 
neovascularization or re-endothelialization (106). 
 The functional capabilities of EPCs can be assessed with clonogenic assays, such 
as the CFU-Hill assay, and EPC senescence.  To date, there are few reports regarding 
exercise and EPC function.  Our results showed no difference in CFU-Hill colonies or 
EPC senescence between long-term exercisers and low-active healthy controls.  Contrary 
to our results, EPC-CFUs have been found to increase following 3 months of aerobic 




patients with heart failure (99).  Patients with disease, as those studied by Sarto, et al (99) 
may show greater benefit in EPC colony-forming capacity from exercise training due to 
greater disease-related endothelial damage.  That our study did not find increased EPC 
clonogenic capacity in healthy trained men as Hoetzer, et al (54) reported, may be 
accounted for by differences in the length and intensity of training. Hoetzer, et al reported 
no increase in VO2max with an increase in treadmill walk time following their home-based 
exercise program, indicating that it was a lower intensity program.  Since our group had 
been exercising regularly for over 30 years at moderate to high intensity, including 
regular participation in competitive events, it is possible that any adaptation in clonogenic 
capacity may have occurred earlier in their training history.   These two studies also used 
different assays to assess clonogenic capacity which may explain the different results 
between the two studies, although endothelial cell lineage of the cultured cells from both 
assays have been confirmed (51; 54).  
 
EPCs and Oxidative Stress  
 Oxidative stress in a system is the balance between the pro-oxidant and anti-
oxidant forces in that system.  Antioxidants have been shown to be protective to both the 
vascular endothelium and EPCs by countering insult by ROS. Both EPCs and mature 
endothelial cells express glutathione peroxidase (GPX-1), manganese superoxide 
dismutase (mnSOD), and catalase although EPC have higher levels of such enzymes (25; 
49); a characteristic of stem and progenitor cells.  Despite heightened defenses, EPC 




 Elevated plasma oxidized LDL levels have been shown in patients with CAD and 
predicts future cardiovascular events in these patients (107; 108). Oxidized LDL is 
associated with activation of monocytes and increased trans-endothelial migration which 
promotes atherosclerosis (131).  OxLDL decreases EPC clonogenic capacity (66), 
increases senescence (63; 82), and decreases VEGF-stimulated differentiation (62) of 
cultured EPCs. We found that oxidized LDL was a significant predictor of EPC function 
in healthy men such that greater OxLDL was predictive of lower CFU-Hill colonies.  To 
our knowledge, this is the first report of in vivo evidence that OxLDL has a significant 
effect on EPC function in healthy individuals.  OxLDL has been shown to decrease Akt 
phosphorylation, eNOS mRNA and protein expression, and EPC nitrite concentration in a 
dose-dependent manner (82).  Therefore, although we did not observe any differences in 
plasma nitrite concentration, it is possible we may have seen a relationship with OxLDL 
and CFU-Hill levels if nitrite was measured directly from EPCs.  
 Cellular senescence is an indicator of exhaustion of the replicative potential of a 
cell (30) and higher EPC senescence has been related to increased cardiovascular risk 
(51). This is the first study to our knowledge to assess EPC senescence, oxidative stress 
and exercise.  We found that plasma TAC was a significant predictor of the change in 
EPC senescence in athletes who stopped exercising for 10 days, such that decreased EPC 
senescence with detraining was related to increasing TAC.   Intense exercise training has 
been shown to decrease antioxidants in the blood (12) and 10 days of physical inactivity 
may have allowed TAC to recover in these athletes.  Although these results are 




studies are needed to elucidate the relationship of specific antioxidant enzymes in EPCs 
such as GPX-1, mnSOD, and catalase with exercise training and inactivity. 
 
Summary 
 We found evidence that CD34+/KDR+ EPC number is closely associated with the 
forearm blood flow response to reactive hyperemia in healthy men.  Further, EPC 
function was influenced by plasma oxidized LDL and the change in EPC senescence was 
related to plasma TAC with cessation of training.  Since EPCs have been shown to be 
related to endothelial function and cardiovascular disease, these results are important to 
the understanding of factors that influence their number and function in healthy men.  
The results of this study highlight the individual variability in factors that may influence 
cardiovascular disease and the need to understand mechanisms that may be responsible 
for these individual differences in disease risk.  Such understanding will enhance 















Hypothesis #1 : Long-term physical activity is associated with improved endothelial 
function which is related to greater EPC number, EPC-Colony Forming Units (CFU-
Hill), and lower EPC senescence compared to age and gender-matched low-active 
healthy individuals.   
 Contrary to our hypothesis, there was no difference between long-term exercisers 
and age- and BMI-matched low-active control participants for EPC number, CFU-Hill 
colonies, or EPC senescence.  However, EPC number was related to resting FBF in 
athletes and AUC1min, and excess flow in control participants and CFU-Hill colony 
number was correlated with the % change in FBF and % change in FVR with reactive 
hyperemia. 
 
Hypothesis #2 : Oxidative stress is lower in long-term exercisers compared to low-active 
controls and is associated with greater EPC number and CFU-Hill count and lower EPC 
senescence. 
 Contrary to our hypothesis, low-active control participants exhibited higher total 
antioxidant capacity compared with long-term exercisers. Regression analysis revealed 
that CFU-Hill count was related to OxLDL in control subjects and entire group 
combined. 
 
Hypothesis #3: EPC number, CFU-Hill count and EPC senescence will deteriorate 
following 10-days of training cessation and these changes will be associated with 




 CD34+ (hematopoietic progenitor cells) decreased and EPC senescence showed a 
tendency to improve with 10 days of training cessation.  CD34+/KDR+ cells decreased in 
5 of the athletes.  This response was related to decreasing FBF response to reactive 
hyperemia.  Five athletes did not have a change in CD34+/KDR+ cells with cessation of 



























REVIEW OF LITERATURE 
 
 
Endothelial Progenitor Cells: Definition and Function 
 
 The development of new blood vessels, or angiogenesis, and re-endothelialization 
was long believed to occur via existing vascular and endothelial cells.  On the other hand 
vasculogenesis is the formation of new vessels from stem cells or progenitors.  In 1997, 
Asahara, et al (6) was the first to identify a population of endothelial progenitors by cell 
surface antigens that differentiated into endothelial cells and incorporated into sites of 
angiogenesis.  These cells, endothelial progenitor cells (EPCs), were later found to also 
participate in endothelial regeneration and repair.  In 1998, Shi, et al (106) discovered 
that these cells rapidly colonized a graft placed in the canine aorta and Walter, et al (130) 
found that EPCs home or migrate to balloon-injured arterial segments and re-
endothelialize the denuded areas.  In addition to neovascularization and re-
endothelialization, these bone marrow-derived cells have been implicated in tumor 
vascularization, wound repair, and recovery from cardiac and limb ischemia. 
 Stem cells occur as both embryonic stem cells and postnatal stem cells.  Postnatal 
stem cells are quiescent until activated by physiological or pathological stimuli for tissue 
regeneration.  Pluripotent stem cells differentiate into ectodermal, mesodermal, and 
endodermal stem cells which give rise to tissue-specific stem cells.  In the bone marrow, 
mesodermal stem cells differentiate into hemangioblasts which differentiate into 
hematopoietic stem cells (HSCs), which are the precursors for lymphoid cells (T-
lymphocytes, B-lymphocytes), myeloid cells (i.e. monocytes, erythrocytes, granulocytes), 




share several common cell surface antigens, such as Flk-1, Tie-2, c-Kit, CD133 and 
CD34, evidence that supports a common precursor, the hemangioblast (5). 
 
Characterization and differentiation 
 The phenotypic characterization of these cells has been and remains controversial 
as there are several possible sources of endothelial cells that can be isolated from the 
blood.  These include hematopoietic stem cells, myeloid cells, circulating mature 
endothelial cells that have sloughed off the vessel wall, and other circulating progenitor 
cells or “side population” cells (123), which possess stem cell characteristics and may 
function to maintain tumors (40; 52).  Identification via surface proteins or antigens can 
be used to characterize EPCs; however, many of the above mentioned cell types have 
similar expression of surface proteins, including CD31, CD34, and KDR (VEGFR-2).  
Difficulty in defining EPCs also comes from the changes in cell surface markers that 
occur on EPCs as they mature.  For example, the antigen AC133 (aka CD133), a five-
transmembrane glycoprotein, is expressed on early bone marrow EPCs but is lost once 
they differentiate into mature endothelial cells (5). 
 EPCs can be isolated from either bone marrow or peripheral blood via surface 
markers and fluorescence-activated cell sorting (FACS); however as mentioned above, 
they likely will have different surface marker phenotypes depending on their origin and 
stage of development.  Immature EPCs isolated from the bone marrow have the general 
phenotype CD133+/CD34+/VEGFR-2+/VE-cadherin-.  EPCs isolated from peripheral 
blood have the general phenotype CD133+/-/CD34+/-/VEGFR-2+/CD14-/VE-cadherin-




CD34+/-/ VEGFR-2+/ CD14-/ VE-cadherin+/ eNOS+/ von Willebrand factor+.  Currently, 
the timing and location of the maturation process is not clear.  EPCs appear to lose 
CD133 in systemic circulation, however, this may also occur prior to release from the 
bone marrow.  In addition, the definition of when an EPC becomes a mature EC is also 
not clear.  Some regard the presence of von Willebrand factor and other EC-like 
characteristics as the determining factor; however this has not been standardized.  Also, 
this phenotype may occur after homing or after incorporation into the existing 
endothelium (59). 
 Further difficulty in isolating EPCs arises from another monocytic-like 
endothelial progenitor cell population that has been found to have the capacity to re-
endothelialize following balloon vessel injury (35; 47).  These cells were isolated from 
bone marrow, had a CD14+/CD34- phenotype, and developed into endothelial cells (ECs) 
although it is reported that they can differentiate into macrophages, dendritic cells, or EC 
depending on environmental cues.  Awad, et al (11) reported that CD14+/CD34- cells 
may have a better capacity to promote vascular growth and healing in vivo than CD34+ 
cells in diabetic patients, a patient population that has decreased function of CD34+ 
progenitors.  Therefore, defining EPCs remains controversial and crucial given that there 
appears to be more than one population of cells that can differentiate into endothelial 
cells and not all stem cells or stem cell lineages may have been characterized.  
 EPCs can also be defined using cell culture and assessing functional 
characteristics.  For example, EPCs can form colony forming units (CFUs) and capillary 
tubes and secrete nitric oxide, typical of ECs.  EPCs also form monolayers with a 




utilization of proliferative potential has become another way to characterize EPCs, which 
has led to the conclusion that cells formerly classified as EPCs represent a heterogeneous 
group of cells that have various in vitro characteristics (65; 93; 143).  Therefore, both 
physiological and functional characteristics have been used to define EPCs and 
phenotypic characterization has emerged as an important method to verify conclusions 
regarding cell populations. 
 
Mobilization and factors influencing EPC mobilization 
 EPCs are released from the bone marrow in response to a variety of growth 
factors, enzymes, ligands and surface receptors.  Stem cells reside in the bone marrow 
stromal cells or stem cell niche.  Generally, activation of the protease matrix 
metalloproteinase-9 (MMP-9) cleaves membrane-bound Kit ligand (mKitL) to a soluble 
Kit ligand (AKA stem cell factor). This allows cKit+ hemangioblast cells to move into the 
vascular zone of the bone marrow, where further proliferation occurs and early EPCs 
enter the blood stream. 
 Currently, there are several stimuli that have been associated with the induction of 
EPC mobilization in that they have been shown to increase circulating EPCs. These 
factors include VEGF, stromal cell -derived factor-1 (SDF-1), granulocyte macrophage 
colony-stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), 
erythropoietin (Epo), HMG CoA reductase inhibitors (statins), PPARγ agonists, 
angiopoietin-1, exercise, estrogen, and eNOS (4; 60; 123).  Ischemia has been recognized 
as a major factor that increases neovascularization and circulating EPCs and may 




the site of injury.  Certainly, VEGF, SDF-1, exercise, and Epo may all stimulate the 
release of EPCs via an ischemic response pathway.   
 VEGF and SDF-1 are released by cells in areas of ischemia and have been 
identified as the major regulators of EPC mobilization in response to ischemia.  Asahara 
et al (7) found that VEGF administration resulted in increases in EPC number and 
enhanced neovascularization.  SDF-1 was found to increase EPC mobilization (85) and 
recently a possible mechanism has been uncovered involving SDF-1 and the interaction 
with its receptor CXCR-4 (69).  In particular, Sbaa, et al (100) showed that caveolin 
deficient mice, that is mice with cells that could not form caveolae used for receptor 
internalization and signal trasduction, did not release EPCs from the bone marrow in 
response to SDF-1.  Therefore, one way that EPCs may be mobilized through SDF-1 
stimulation is via CXCR-4 receptor internalization.  There is evidence that calveolin may 
act via eNOS, which appears to be an important factor in EPC mobilization in response to 
VEGF (reviewed below).  Brouet, et al (16) reported that statins down-regulated the 
expression of caveolin in ECs and promoted NO-dependent angiogenesis in vitro. The 
same group, (110) later found that EC caveolin activity and the ability to 
compartmentalize VEGFR-2 receptors in caveolae was critical to eNOS stimulation via 
VEGF and neovascularization.   Therefore, caveolin may play a role in ischemia-induced 
EPC mobilization via VEGF and SDF-1. 
 eNOS has been recently found to be an important regulator of EPC mobilization.  
eNOS deficient mice have impaired ischemia-induced neovascularization and decreased 
EPC mobilization in response to VEGF (88).  Dimmeler’s group (3) reported that 




in proMMP-9, which led to a decrease in soluble Kit ligand and release of Kit+ cells from 
the stromal cell niche. eNOS is also likely involved in EPC mobilization in response to 
estrogen.  Two separate groups, Iwakura, et al (68) and Strehlow, et al (112), showed that 
estrogen increases circulating EPC number, however, Iwakura, et al also reported that 
estradiol enhances recovery after MI by activating eNOS and MMP-9, thereby increasing 
EPC mobilization.  Statins have been demonstrated to induce the release of EPCs (26; 80) 
as well as up-regulate the expression of eNOS.  Dimmeler, et al showed that EPC 
mobilization occurs via the PI-3 kinase/Akt pathway, a pathway that plays a role in 
endothelial cell survival by inhibiting apoptosis and stimulating NO synthesis (26).  
Lastly, exercise may also work to increase circulating EPCs through the increased nitric 
oxide production and bioavailability that accompanies exercise training (78).  Therefore, 
eNOS appears to play an important role in EPC mobilization in response to ischemia-
induced VEGF production, estrogen, and statins. 
 Angiopoietin-1 (Ang-1) is a growth factor expressed in endothelial and 
developing vascular cells which works via the Tie-2 receptor tyrosine kinase. 
Angiopoietin-1 enhances endothelial cell survival, capillary development, and also limits 
vascular permeability.  Hattori, et al (48) found that Ang-1 promoted the mobilization of 
HSCs and circulating endothelial progenitors.  In this study, when Ang-1 and VEGF were 
given together, more cells were mobilized.  This group also demonstrated that while 
VEGF induced a rapid release of EPCs, Ang-1 caused a delayed mobilization of EPCs, 
which in combination produced a prolonged EPC release (85).  Although the researchers 
hypothesized that Ang-1 may alter the adhesion of progenitors to the bone marrow 




 G-CSF and GM-CSF are some of the most powerful stimulants of EPC 
mobilization. G-CSF is released by endothelial cells and macrophages and induces the 
bone marrow to release granulocytes, a type of white blood cell which plays a role in 
atherosclerotic fatty streak formation and progression to a complex fibrous lesion. Natori, 
et al (89) found that G-CSF increased tumor neovascularization and that bone marrow-
derived EPCs participated in this effect in mice.  GM-CSF is a protein released by 
macrophages that stimulates stem cell differentiation of granulocytes and macrophages 
and therefore is part of the inflammatory cascade.  Asahara’s group (114) found that 
cytokine therapy with GM-CSF mobilized EPCs and improved vascularization to 
ischemic areas in mice and rabbits.  In addition, cytokine therapy with G-CSF was shown 
to increase the release of kit+/flk1+ cells by 9-fold in rats and these cells were found to 
directly contribute to endothelial regeneration (115).  However, in a recent study, 
Dimmeler’s group found that although G-CSF therapy increased circulating EPCs and the 
number of colony-forming units produced in patients with ischemic heart disease, the 
functional activity of the EPCs (assessed by migration to VEGF and SDF-1) was reduced 
(57).  In the same study, the group found similar results in treated mice in addition to 
reduced in vivo capacity to augment blood flow recovery and to prevent necrosis by 27%.  
Therefore, although some have considered the use of G-CSF a potential therapy for re-
endothelialization following vascular injury, others have recognized that due to the 
association with inflammation and other potential negative consequences, these factors 
may not be an optimal in the induction of EPC release as a future therapy (4). 
 Many of the other factors identified as increasing EPC mobilization may work via 




investigated and clarified. For example, PPARγ agonists have been shown to increase 
EPC number and migratory activity in type 2 diabetic patients (91) and PPARγ agonists 
have been shown to attenuate the negative effects of CRP on EPC survival differentiation 
and function (128). Although PPARγ activation has been associated with cellular 
differentiation and inhibition of endothelial dysfunction, atherosclerosis, and restenosis, 
the mechanisms behind these effects are not clear.  Recently, it was found that the PPARγ 
agonist, thiazolidinedione (TZD) increased EPC number and migration in patients with 
CAD and normal glucose tolerance.  Cell culture experiments revealed that TZD 
treatment decreased NADPH oxidase, a producer of endothelial superoxide free radicals 
and decreased EPC apoptosis (134). Although this study showed that oxidative stress 
may influence EPC function, a connection between oxidative stress and EPC 
mobilization is not yet clear.  Therefore, there may be mechanisms that increase the 
mobilization of EPCs from the bone marrow that are still unknown. 
 Several pathological factors have been found that lead to increases in number and 
function of putative EPCs.  For example, acute myocardial infarction (109) and class I-II 
congestive heart failure (124) have been shown to increase EPC number.  Associated 
CVD conditions found to decrease EPC number and function are hypertension, increased 
number of CVD risk factors, smoking, family history of CVD (126), cumulative risk 
factor score (51), and class III-IV CHF (124).  Certainly, many of these pathological 
factors may work via similar mechanisms stated above (VEGF and NOS) to increase 
EPC mobilization.  Currently, there are few studies that have investigated the 




possible that the pathology of diseases associated with reductions in EPC numbers (such 
as hypertension) may be due to decreased eNOS or other unidentified factors.  
 Recently, reactive oxygen species have been hypothesized as having an effect on 
mobilization, homing, incorporation and survival of EPCs.  Like all stem cells, EPCs 
have been shown to have an increased capacity to resist ROS as they have high levels of 
antioxidant enzymes.  Dernbach, et al (25) showed that EPCs have increased expression 
of catalase, glutathione peroxidase and manganese superoxide dismutase (MnSOD), 
compared to HUVECs or human microvascular endothelial cells.   However, some 
disease states such as diabetes, hypertension and CVD, which are associated with 
increased ROS production, have been associated with decreased number, function, or 
survival of EPCs.  For example, EPC senescence is accelerated in rats and human patients 
with hypertension (64).  Galasso, et al (36), found that glutathione peroxidase (GPx-1) 
deficient mice had impaired mobilization, and migration of EPCs, as well as a reduced 
capacity to neutralize ROS, increased ROS-induced apoptosis, and decreased 
angiogenesis in ischemic tissue.  Additionally, Ma, et al (82) recently reported that 
OxLDL, which is oxidized by ROS in the endothelium during the process of 
atherosclerosis, impairs EPC survival via the inhibition of eNOS.  Therefore, EPC 
function in CVD may be closely related to increases in ROS associated with CVD. 
 
Homing and endothelial incorporation 
 Currently, the mechanisms of how EPCs function in neovascularization and re-
endothelialization are not completely understood.  It has been established that EPCs 




signals that stimulate EPCs to home to the site of injury and incorporate into the 
endothelium are not well characterized as most of the available literature provides only 
indirect evidence of mechanisms.  In the case of re-endothelialization, homing includes 
signals that localize EPCs to the site of injury or chemotaxis, adhesion of EPCs to the 
endothelial surface, transmigration and incorporation into the endothelial wall and 
differentiation into endothelial cells or other vascular cells.  Recently some factors have 
been identified that may be involved in the homing and incorporation of EPCs into the 
endothelium. Interestingly, many of these factors are similar to those that induce 
mobilization. 
 Stromal cell-derived factor-1 (SDF-1) has emerged as one of the major signals 
that attract EPCs to the site of injury, or chemotaxis.  SDF-1 and its receptor, CXCR4, are 
known to be required for stem cell homing to bone marrow.  Recently, the CXCR4 
receptor has been shown to also be important in EPC homing to vasculature in ischemic 
tissue.  In this study, Sbaa, et al (100) found that inhibiting the sequestration of CXCR4 
receptors into calveolae improved homing to ischemic tissues.  Not only do SDF-1 and its 
receptor appear to be important to EPC homing, but SDF-1 has been shown to attract 
EPCs.  Yamaguchi, et al (140) found that greater numbers of labeled EPCs migrated to 
areas of ischemia when SDF-1 was administered locally. EPC incorporation at day 3 was 
1.8-fold higher than the control group, but similar between days 3-7.  In addition, SDF-1-
administered mice had greater capillary density at day 28, which demonstrated that 
improvements in angiogenesis were a result of early SDF-1 exposure.  They were also 
able to demonstrate a strong dose-dependent migratory response of EPCs toward SDF-1 




protein in ischemic muscles.  They did, however, show increases in VEGF mRNA in 
ischemic tissue in the SDF-1 treated mice.  SDF-1 is released in response to ischemia as 
Askari, et al (8) reported an increase in SDF-1 immediately following (1h-24h) MI in 
mice. Therefore, it is not clear how SDF-1 works to home EPCs to the site of injury or 
ischemia, however, it appears to be an important factor in the acute response to damage. 
 VEGF appears to be another factor that may be a chemoattractant for EPCs to 
home to a site of injury/ischemia.  Asahara, et al (7) demonstrated that bone marrow 
mononuclear cells, cells considered upstream to differentiated EPCs and cultured EPCs, 
displayed chemotaxis toward VEGF in vitro. In addition VEGF administration improved 
neovascularization of the cornea. As mentioned above, VEGF mRNA was increased in 
ischemic tissue of SDF-1-treated mice, which may indicate that the two factors work 
together to attract EPCs to injury.  Further, VEGF increases acutely (up to day 7) 
following MI, which is accompanied by an increase in circulating EPCs (109).  EPCs 
migrate toward VEGF in vitro and the migratory capacity of isolated EPCs to VEGF or 
SDF-1 was found to be related to the functional improvement in MI patients following 
stem cell therapy (15). 
 Apoptosis, thrombin and platelets appear to be other factors that may stimulate 
EPC homing.  In 2004 Hristov, et al (58) found that apoptotic bodies from endothelial 
cells stimulated the proliferation and differentiation of EPCs in vitro.  Thus, endothelial 
cells that go through apoptosis may serve as a signal to circulating EPCs to the location 
of injury.  Thrombin, the coagulation factor that has been shown to play a role in post 
injury inflammatory responses, has recently been found to promote EPC differentiation 




thrombus resolution.  Therefore, in the case of thrombosis, EPCs may locate the injury 
via thrombin.  More recent evidence shows that platelets may play a role in the homing of 
EPCs to sites of vascular lesions (75).  Therefore, it appears that signals associated with 
vascular damage, such as EC apoptosis, thrombin and platelets are signals for EPC 
homing to that site of damage. 
 Following homing to the site of injury, EPCs must incorporate into the vascular 
wall and differentiate into mature EPCs.  Integrins, adhesion molecules, and possibly 
vascular endothelial cadherin (VE-cadherin) have been recently found to participate in 
the incorporation of EPCs into an existing endothelium.  In their study showing the effect 
of platelets on EPC homing, Langer, et al (75) also reported that adhesion of EPCs to 
platelets is inhibited by neutralizing β1 integrins.  Other recent findings have shown that 
the integrin α4β1, which is expressed on EPCs, binds to the endothelial cell ligands 
VCAM and fibronectin, which are expressed on actively remodeling new vasculature 
(70).  Similarly, Yoon, et al (144) found that ischemia induced intracellular adhesion 
molecule – 1 (ICAM-1) expression on endothelial cells, which bound EPCs via ICAM-
1/β-2 integrins in vitro.  In this study, in vivo results showed that EPCs preferentially 
homed to ischemic muscle and blocking ICAM-1 expression decreased this effect with 
accompanying decreases in neovascularization.  VE-cadherin is expressed on endothelial 
cells and is required for EC-cell interaction as well as maintenance of EC integrity and 
barrier function.  Kogata, et al (72) found that ischemia induced VE-cadherin expression 
in existing ECs and bone-derived cells and that VE-cadherin-activated bone-derived cells 
were found surrounding the ischemic area.  These researchers hypothesized that this may 




Therefore, more information is needed regarding the stimuli that effect EPC homing and 
incorporation into the existing endothelium. 
 Recent evidence appears to show that homing and incorporation of EPCs may not 
simply be a function of signal molecules released from the area of damage, but EPCs 
themselves have also been shown to express several growth factors, such as VEGF, SDF-
1, and insulin-like growth factor-1 (IGF-1), which may not only work in the migration 
and homing of EPCs, but may also supply the surrounding existing differentiated cells 
with factors to support their survival and function (122). Other recent data show that 
progenitor cells may not only be derived from the bone marrow, but from a 
“vasculogenic zone” that lies between the smooth muscle and adventitia.  These cells 
were CD34+ but CD31- and termed vascular wall EPCs or VW-EPCs (146). These cells 
were capable of forming capillary sprouts and became positive for endothelial markers 
VEGFR-2, Tie-2, and VE-cadherin and had the capacity to differentiate into ECs.   
 Therefore, as more information is gained regarding EPCs, it appears that these 
cells have multiple strategies to aid in successful neovascularization and re-
endothelialization.  Not only are several redundant factors involved in their stimulation of 
mobilization and homing, but they have increased capacity to neutralize ROS, may have 
more than one source, and may themselves release factors that aid in their survival. 
 
Endothelial Progenitor Cells and Cardiovascular Disease 
In 2001, Vasa, et al (126) were the first to report an association between the 
number and function of endothelial progenitor cells with coronary artery disease family 




patients with a positive family history for CAD and impaired EPC migratory response in 
patients with a greater number of atherosclerotic risk factors.  EPC number and function 
have also been found to be associated with endothelium-dependent flow-mediated 
vasodilation, a measure of endothelial function (50; 51; 135).  Interestingly, the number 
of EPCs was found to be a better predictor of vascular reactivity than the Framingham 
risk factor score (51).  The number of circulating EPCs was found to independently 
predict atherosclerotic disease progression (103) and cardiovascular events including 
death from cardiovascular causes, revascularization surgery, and hospitalization due to 
cardiovascular events, which included angina, congestive heart failure, stroke, 
myocardial infarction, and arrhythmia (133). 
 
Mechanisms relating EPCs to CVD 
 Atherosclerosis is a hallmark of CVD.  It is commonly accepted that 
atherosclerosis begins as dysfunction and damage of the endothelial layer.  Endothelial 
damage leads to a cascade of proinflammatory events, infiltration of monocytes, adhesion 
molecule expression and smooth muscle cell proliferation which result in atherosclerotic 
lesions (96). Current risk factors for CVD share a common mechanism, which is 
endothelial damage.  The endothelium is constantly repaired by two mechanisms; from 
pre-existing, fully-differentiated endothelial cells and bone-derived endothelial progenitor 
cells.  The existing mature cells may have a limited proliferative potential and their 
capacity to repair a damaged endothelium may be restricted.  EPCs, on the other hand, 




 EPCs are released from the bone marrow by a variety of signals, including VEGF, 
SDF-1, G-CSF, GM-CSF, and eNOS (as discussed above).  Ischemic tissues release 
VEGF and SDF-1, which likely explains the increase in EPCs in response to myocardial 
infarction (109).  In this case, the angiogenic capacity of EPCs is valuable in working to 
revascularize the damaged tissue. In fact, exogenous EPCs have been used in humans for 
both clinical cardiac repair resulting in improved ejection fraction, end systolic LV 
volume (10) and enhanced contractile motion and neovascularization of occlusive arterial 
disease, improving transcutaneous oxygen pressure, and decreasing resting and walking 
pain (81). 
 EPCs are also mobilized by factors that are present in the process of 
atherosclerosis and associated inflammation.  In addition, thrombin (116) and platelets 
(75) have also been shown to be involved in the differentiation and homing of EPCs to a 
site of injury.  This is further evidence that endogenous EPCs function in the repair of 
vascular damage of atherosclerosis progression. Schmidt-Lucke, et al, (103) reported that 
the number of circulating EPCs independently predicted atherosclerotic disease 
progression in patients with CVD, which was determined by the need for coronary 
revascularization of de novo lesions due to ischemia.  In this study, patients with lower 
EPC number had a 4-fold increased risk of suffering a CVD event during the follow-up 
period.  Therefore, the number of circulating EPCs is correlated with event-free survival 
in CVD. 
 In the examples of MI and atherosclerosis, EPCs are important in vascular repair 
and regeneration following a CVD event or overt vascular disease.  Impaired endothelial 




function, such as the decrease in nitric oxide and eNOS, have been shown to precede 
atherosclerosis and reflects both potential and existing atherosclerosis.  Endothelial 
function has also been shown to be a prognostic indicator of atherosclerosis and clinical 
cardiovascular events (113).  EPCs likely are involved in ongoing endothelial repair as 
they may serve as a pool of cells that home to a site of injury.  As mentioned above, 
EPCs home to an endothelial cell-denuded arterial section and re-endothelialize the 
region (130).  Over time, endothelial cells undergo replicative senescence as they are 
exposed to stressors. Endothelial dysfunction has been related to senescent changes in 
endothelial cells such as decreases in telomere length and telomerase (141) and increases 
in the cell-senescence indicator, β galactosidase.  Minamino, et al (84) showed that 
endothelial cells that overlay atherosclerotic plaques show an enhanced senescence-
associated phenotype (increased β galactosidase staining).  Injury to endothelial cells is 
often followed by apoptosis which has been regarded as a critical step in the progression 
of atherosclerosis (96).  Recently, Hristov, et al (58) found that apoptotic bodies from 
endothelial cells stimulated EPC differentiation in vitro.   Hill, et al (51), reported that 
number of circulating EPCs were related to flow-mediated brachial reactivity, an 
assessment of endothelial function.  In this study, lower numbers of EPCs was related to 
lower endothelial function.  Therefore, overall endothelial damage may be represented by 
the balance between the magnitude of injury and the capacity for repair and EPCs may be 
important for the maintenance of a healthy, functional endothelium. 
 Currently, it is unknown why EPCs appear to be decreased in response to 
excessive or continuous damage or stress.  There may be a few possible explanations.  




progenitor cells in the bone marrow.  There has been an association of age with decreased 
EPC number in that increased age is correlated with decreased EPC number (28; 139) 
which may led evidence to this theory.  However, recently, Chen, et al (18) reported that 
there was no association of age and basal EPC number in healthy individuals who did not 
have any CVD risk factors, although this does not preclude the possibility that EPC 
mobilization to a stimulus such as VEGF is not attenuated with age.  Therefore, it is 
unclear whether chronic stress decreases EPC number by depletion of the EPC pool.  
Second, chronic stress on the endothelium may decrease EPC mobilization.  Decreased 
NO is a hallmark of endothelial dysfunction and eNOS is an important regulator of EPC 
release from the bone marrow.  eNOS deficient mice show reduced EPC mobilization in 
response to ischemia (3) or exercise (78).  Lastly, chronic stress and CVD risk factors 
may affect the differentiation and/or incorporation of EPCs into the endothelium by 
damaging EPCs directly.  For example, Hill, et al (51) found that EPCs from patients 
with a higher risk for cardiovascular events demonstrated greater in vitro β-galactosidase 
activity, an indicator of cellular senescence.  It was recently reported that EPCs from both 
spontaneously hypertensive rats and human patients with essential hypertension 
demonstrated increased EPC senescence and decreased EPC telomerase activity (64).   
Senescent EPCs would not have the proliferative capacity of normal EPCs and may not 
have the ability to differentiate and incorporate into the endothelium as effectively.  
Oxidative stress produced from CVD risk factors could also damage EPCs.  Galasso, et al 
(36) reported that glutathione peroxidase (GPx-1) deficient mice had impaired 
mobilization and migration of EPCs, as well as a reduced capacity to neutralize ROS, 




Certainly, decreases in the ability of EPCs to repair an injured endothelium may be 
caused by all three of these factors, or even perhaps factors that have not yet been 
identified.  
 Therefore, although not all details of mechanisms regarding the way in which 
EPCs work in the cardiovascular system to maintain vascular function, most data show 
that EPCs not only are mobilized to neovascularize and re-endothelialize damaged tissue, 
but that they may be an important coomponent of maintaining a healthy endothelial layer, 
which may become damaged over time and lead to endothelial dysfunction, 
atherosclerosis and CVD. 
 
Studies relating EPCs to CVD  
 Currently, there are several studies that have associated EPC number with 
cardiovascular diseases.  Some CVD-related factors have been shown to be associated 
with an increase EPC number.  Acute myocardial infarction (109; 137), vascular injury 
(68), and class I-II congestive heart failure (124) have all been shown to increase EPC 
number.  MI and vascular injury represent an acute response to injury in which EPCs 
would be mobilized.  Associated CVD conditions found to decrease EPC number and 
function are hypertension, increased number of CVD risk factors, smoking, family 
history of CVD (126), cumulative risk factor score (51), and class III-IV CHF (124).  In 
the case of CHF, Valgimigli, et al (124) attributed the increase in EPCs in the early stages 
and decrease in later stages to TNF-α, which is an inflammatory cytokine that is 




hematopoiesis which may overwhelm the mobilization signal seen in the early stages of 
the condition. 
 There are a few studies that include individuals with CVD or various degrees of 
CVD risk that show a relationship of EPCs and CVD risk factors, endothelial function, 
and/or CVD progression and prognosis. In a prospective study in 2001, Vasa, et al (126) 
were the first to report an association between the number and function of these cells with 
coronary artery disease family history and number of atherosclerotic risk factors.  In a 
study with 45 patients with CAD and age-matched controls, they reported ~40% lower 
EPC number in patients compared to controls.  In only the patient group, the number of 
risk factors was correlated with decreased EPC number.  Impaired EPC migratory 
response was correlated with a greater number of atherosclerotic risk factors.  Hill, et al 
(51), studied 45 men with various CVD risk factors but no history of CVD and found 
EPC function (assessed by colony-forming assay) was associated with endothelium-
dependent flow-mediated vasodilation, a measure of endothelial function and precursor to 
CVD.  Interestingly, in this study, the number of EPCs was found to be a better predictor 
of vascular reactivity than the Framingham risk factor score (51).  In a study by Schmidt-
Lucke, et al (103), 120 individuals (43 controls, 44 patients with stable CAD, and 33 with 
acute coronary syndromes) were followed for atherosclerotic disease progression and 
acute coronary events.  The number of circulating EPCs was found to independently 
predict atherosclerotic disease progression assessed by the need for coronary 
revascularization of de novo lesions, and future cardiovascular events including death 
from cardiovascular causes, unstable angina, or myocardial infarction.  In the same year, 




and the relationship between EPC number and colony-forming units and outcomes over a 
12 month period.  Patients with the lowest EPC number had significantly higher 
incidence of death from CV causes.  Low EPC numbers did not predict death from all 
causes.  In addition, this group found similar results of Hill, et al (51), in that EPC 
function, assessed by colony-forming units, was impaired in a subgroup of patients.  
Therefore, not only EPC number, but EPC function influences cardiovascular outcomes.  
In a study on cerebrovascular disease, Ghani, et al (37) found that EPC number was 
significantly lower in patients with stroke compared to control subjects.  In addition, they 
reported a significant inverse relationship between EPC number and Framingham risk 
factor score.  This study supports the data that EPCs function as a factor that works to 
maintain the endothelial monolayer. 
 EPCs (and other progenitors) have become an experimental novel therapy to 
improve cardiac function following myocardial infarction (MI) and stroke.  In this case, 
EPCs likely improve neovascularization in an ischemic region, but also have been shown 
to differentiate into cardiac myocytes (27).  The BOOST trial was the first randomized-
controlled trial using bone-derived progenitor (CD34+) cells.  This group reported 
improved left ventricular function in myocardial infarction patients (measured via left-
ventricular ejection fraction) 6 months following bone marrow cell transplantation (138).  
In the TOPCARE-AMI trial patients with acute MI underwent progenitor cell 
transplantation.  Cells were either bone marrow- (CD34+/CD45+/CD133+) or blood-
derived (VEGFR2+/von Willebrand factor+/ PECAM-1+/VE-Cadherin+).  Regardless of 
the type of cells transplanted, 4 months post AMI, treated patients had a significant 




and a significant reduction in end-systolic LV volumes (9).  The one-year follow-up of 
this study showed increased ejection fraction, decreased infarct size, and no indication of 
reactive hypertrophy (101).  Although the means by which the administered progenitor 
cells function has not been directly measured in these cases, exogenous progenitor cell 
administration appears to improve prognosis following acute MI. The optimal cell 
population to use, method to mobilize and isolate the cells, and methods to optimize 
downstream cell function has yet to be elucidated. 
 These studies relate EPC number and function to CVD disease progression and 
prognosis in patients with established CVD.  Currently, there are no long-term studies 
investigating EPC number or function in healthy patients with CVD development.  These 
large population-based studies are crucial in the determination of factors as those that 
cause CVD.  As EPCs are not routinely measured, and the nature of measuring EPC 
number and migration require a fresh blood sample, retrospective studies are not possible 
to relate aspects of patient history to disease development.  Therefore, although the above 
studies provide strong evidence, data from longitudinal studies will be needed to 
convincingly regard EPCs as a CVD risk factor. 
   
Interrelationships of EPCs and CVD risk factors 
 EPCs have been related to many of the established CVD risk factors and have 
shown various degrees of correlation, but overall, an inverse significant relationship 
between the risk factors and EPCs persists.  In the article published by Schmidt-Lucke, et 
al (103), the number of EPCs was correlated with CVD risk factors by univariate 




significantly correlated with EPC number.  Lipids were not included in the analysis.  
Diabetes and hsCRP, however, were not correlated with EPC number.  By multivariate 
analysis, age and family history of CVD remained significant independent predictors of 
reduced EPC number.  In the results from the study by Vasa, et al, (126), using a similar 
analysis researchers reported that smoking was associated with lower EPC number. This 
group also reported that migratory capacity of EPCs was influenced mainly by 
hypertension. LDL cholesterol, family history of CVD, and age were all shown to 
determine the number of circulating EPCs and migration.  In the Bruneck study, a large 
population-based study, EPC number (evaluated via cell-culture assay) and EPC-CFUs 
were measured in over 500 participants (139).  Contrary to expectations, EPC number 
was positively correlated with Framingham risk score although a negative relationship 
was found between EPC number and extent of carotid atherosclerosis.  Researchers also 
demonstrated decreasing EPC number with increasing age, a finding that has not been 
consistently found.  A possible explanation for these results could be the technique used 
to quantify EPC number, as EPCs derived from culture have not been found to correlate 
with those quantified via flow cytometry (31).  However, increased circulating EPCs with 
increased Framingham CVD risk may be indicative of cardiovascular stress or vascular 
damage that signaled the mobilization of EPCs.  
 There are several studies that have investigated the relationship of individual risk 
factors including smoking, diabetes, hypertension, and age with EPC number or function. 
Kondo, et al (73) also reported that the number of EPCs was reduced in smokers and that 
smoking cessation led to a rapid restoration of EPC numbers that was greater in light 




potentially explain a mechanism for the increased incidence of CVD in smokers.  
Alterations in EPC function have also been associated with diabetes.  Tepper, et al (117) 
found that EPCs from type II diabetes patients had a 48% decrease in proliferation in 
culture compared to controls.  In addition, EPCs from diabetics had decreased adhesion 
to HUVECS and were 2.5 times less likely to participate in tubule formation compared to 
EPCs from non-diabetic subjects.  These data suggest that patients with type II diabetes 
have impaired EPC function, which may explain the increased incidence of CVD in 
diabetics. Imanishi’s group also found that hypertension in rats and human patients is 
associated with EPC senescence (64).  The relationship of age with EPCs is not clear.  In 
the study by Vasa, (126) which included 45 patients with CVD and 9 controls, they 
showed an inverse relationship of EPC number with age. However, recently, Chen, et al 
(18) reported that in healthy patients with no CVD risk factors, there was no relationship 
between CVD and age.   Physical activity is known to stimulate EPC release (77).  In this 
study there is no mention of physical activity level or participation prior to sample 
collection.  Therefore, it is possible that PA level may attenuate any age-related changes 
observed in EPC number.   
 Plasma lipids, another CVD risk factor, have also been related to EPC number 
and function, although there are not much data in these areas. Tso, et al (121) reported 
that HDL enhanced repair of the endothelium by EPCs in mice. In humans, Pellegatta, et 
al (90) reported that EPC colony-forming capacity was associated with total cholesterol, 
HDL, and the HDL/TC ratio.  These data suggest a synergistic effect of EPCs and HDL, 




 In conclusion, the interrelationships between EPCs and other established CVD 
risk factors, the mechanistic evidence, and population-based study evidence mentioned 
above show that EPCs may be a good candidate for inclusion in the list of CVD risk 
factors.  Currently, the data with EPCs in humans demonstrate that lower EPC number 
and function are correlated with decreased prognosis and outcome in patients with CVD. 
There is, however, a lack of larger, longitudinal studies with healthy individuals 
demonstrating relationships between EPC number and development of CVD.  In the 
future, primary prevention trials which utilize methods to increase EPCs may also help to 
demonstrate that EPC number and function are useful in assessing risk for CVD. 
 
Endothelial Integrity and Oxidative Stress 
 The integrity of the vascular endothelium is determined by the balance of injury 
and repair.  Oxidative stress results when pro-oxidants are greater than antioxidants and 
has been shown to be a significant contributor to CVD via the damaging effects on the 
vascular endothelium.  EPCs work to repair the endothelium and despite the 
characteristic of heightened antioxidant levels, EPCs have been shown to be vulnerable to 
damage induced by oxidative stress.  Oxidative stress-induced damage to EPCs may lead 
to decreased capacity of these cells for repair, thereby resulting in accumulating 
endothelial damage and progression of atherosclerosis and heart disease. 
 
Reactive oxygen species  
 Oxidative stress is cellular damage that is caused by reactive oxygen species 




based substances with an unpaired electron (i.e. hydroxyl radical, OH.) superoxide (O2.-
), peroxynitrite (ONOO.-), nitric oxide (NO), and hydrogen peroxide (H2O2) (94).  With 
an unpaired electron, these molecules are highly reactive and can participate in several 
biochemical reactions.  ROS are produced by several mechanisms.  The three 
mechanisms that are most prevalent in endothelial cells are NADPH oxidase (NOX), NO 
synthase (NOS), and xanthine oxidase (97).   ROS production also comes from 
mitochondrial respiration and the electron transport chain (ETC).  The reduction of 
oxygen to water takes 4 electrons in the ETC.  With each addition of 1 electron, a 
different ROS can be generated (39). ROS can also be produced by cycloxygenases, 
lipoxygenases, and cytochrome p450 monooxygenases.  Factors that stimulate ROS 
pathways which are important in endothelial cells include homocysteine, ANGII, TNF-α, 
platelet-derived growth factor (PDGF) and glucose.  
 ROS can exert cellular damage in many ways, including DNA damage, cellular 
senescence, and apoptosis.  Recently, Demirbag, et al (24) found that patients with CAD 
had decreased plasma total antioxidant capacity and increased leukocyte DNA damage.  
ROS can oxidize nuclear and mitochondrial DNA (mtDNA).  Involvement of ROS in 
mtDNA damage has been considered the most relevant as mitochondria continuously 
produce O2- and mtDNA is continuously exposed to oxidative stress throughout the 
lifespan (14).  Oxidative mtDNA damage leads to mitochondrial dysfunction, decreased 
numbers of mitochondria, and the formation of dysfunctional mitochondrial proteins, 
which can lead to increased production of ROS and more mtDNA damage (32). 
 Another consequence of ROS-induced DNA damage is cell senescence.  




been found to overlay atherosclerotic plaques (84). Human vascular endothelial cells 
(HUVECs) that have been treated with H2O2 enter senescence earlier than control cells.  
The treated cells also had decreased telomere length, which is an indicator of DNA 
damage and replicative senescence (74). Evidence for the involvement of ROS in this 
telomere-mediated cell senescence and dysfunction via TERT (the catalytic component of 
telomerase) comes from a study by Haendeler, et al (41).  Haendeler and her group have 
identified that oxidative stress leads to nuclear export of TERT through the activation of 
the tyrosine kinase Src, which phosphorylates TERT, which signals the transport of the 
phosphorylated TERT from the nucleus and leaves the cell without the ability to attenuate 
telomere attrition with replication.   
 Cellular apoptosis, or programmed cell death, can also occur when cells are 
damaged by ROS.  Apoptosis refers to the morphological alterations exhibited by 
"actively" dying cells, including cell shrinkage, membrane blebbing, chromatin 
condensation, and DNA fragmentation (29).  ROS have been found to induce endothelial 
cell apoptosis.  Dimmeler et al (29), showed that oxLDL induces apoptosis in HUVECs, 
which was completely prevented by exposure of cells to antioxidants.  Induction of 
apoptosis by ROS appears to be dependent on the species generated and the concentration 
of ROS.  For example, high concentrations of hydrogen peroxide and peroxynitrite 
promote apoptosis and cell detachment and shedding (anoikis) (120).  On the other hand, 
low doses of ROS protect ECs from apoptosis (42).  In 2005, Muakami, et al (86) found 
that hydrogen peroxide stimulated endothelial cell apoptosis via JNK phosphorylation.  
Interestingly, in this study, they also observed that angiopoetin-1 (Ang-1), a hormone 




induced apoptosis by Akt phosphorylation through PI3 kinase.  Therefore, ROS appear to 
affect endothelial integrity by promoting EC apoptosis, however, this effect may depend 
on the species generated and the concentration. 
 Cells have systems, chemicals and enzymes or antioxidants, to combat the 
accumulation of ROS.  Chemical antioxidants are glutathione and other thiols and 
enzymatic antioxidants are cu/zn SOD (SOD-1) located in the cytosol, MnSOD (SOD-2) 
located in the mitochondria, ecSOD (SOD-3) located in the exracellular matrix, 
glutathione peroxidase (GPx), and catalase.  However, oxidative stress occurs when there 
is an imbalance between the two - when prooxidants are greater the antioxidants.  Many 
diseases have been attributed to increases in ROS-induced cellular damage.  In particular, 
cardiovascular disease has been associated with ROS accumulation as ROS promote 
atherosclerosis by factors such as endothelial dysfunction, VSMC migration, monocyte 
migration, and oxidation of LDL.   
 
Oxidative stress and endothelial dysfunction 
 The vascular endothelium has several important functions.  Not only does it 
provide a nonthrombogenic layer for laminar blood flow, but it also senses and 
transduces signals from the circulation.  The endothelial layer is important in the 
maintenance of vascular tone.  Endothelial cells maintain the balance between 
vasodilating factors (ie NO) and vasoconstricting factors (ie. ET-1, ATII).  The 
endothelium also maintains the coagulation state by regulating platelet activation, 
fibrinolytic system and the clotting cascade.  Endothelial cells also regulate the 




and adhesion molecules (97).  The myriad of functions and regulatory processes 
performed by the endothelium reflect a system that is imperative to maintain 
homeostatsis and efficiently repair damage.  Endothelial dysfunction is closely related to 
the development of atherosclerosis as changes in endothelial function, such as the 
decrease in eNOS, have been shown to precede atherosclerosis and reflects both potential 
and existing atherosclerosis.   
 Endothelial damage from ROS can occur via direct and indirect mechanisms.  
Primarily, the endothelium can be damaged such that the bioavailability of NO is 
decreased resulting in endothelial dysfunction.  Endothelial dysfunction is characterized 
by a decrease in NO.  ROS affects the bioavailability of NO in ECs in several ways.  
First, NO synthase, the enzyme that forms NO, can experience “uncoupling”.  NO 
uncoupling was defined by Pritchard et al in 1995 and it occurs when NO reacts with O2- 
to form peroxynitrite (ONOO-).  ONOO- can inactivate mnSOD by tyrosine nitration, 
leading to a lower antioxidant capacity in the cell.  ONOO- can also switch NOS from an 
NO- to an O2- generating enzyme by oxidation of BH4.  BH4 is an essential cofactor that 
maintains eNOS dimer stability.  The net result is a decrease in NO bioavailability, an 
increase in ROS, and a decrease in the antioxidant capacity.  A second mechanism that 
decreases NO in ECs is direct scavenging of NO by oxygen radicals.  Endothelial 
dysfunction can also be caused by tyrosine nitration of prostacyclin synthase by ONOO- 
and decreased prostacyclin availability (14). Endothelin-1 (ET-1) is a vasoconstricting 
substance in ECs.  ET-1 has recently been found to increase ROS production (92). ET-1 





 Loss of endothelial function and integrity via ROS can also occur by stimulating 
adhesion molecule expression which can attract leukocytes and inflammatory substances.  
In endothelial cells, ROS can directly stimulate vascular cell adhesion molecule (VCAM-
1), monocyte chemoattractant protein (MCP-1) and granulocyte-macrophage colony 
stimulatory factor (GM-CSF). VCAM-1 is responsible for the adhesion of monocytes to 
the endothelial cell surface.  Once bound, MCP-1 stimulates the transmigration of the 
monocyte through the endothelium to the subendothelial layer.   GM-CSF is a cytokine 
that targets bone marrow progenitors signaling growth and differentiation.   
 There are several indirect mechanisms by which ROS can induce the expression 
of inflammation-related proteins.  ROS can oxidize LDL, which then can stimulate gene 
expression of VCAM-1 and intercellular adhesion molecule (ICAM-1), another molecule 
responsible for the adhesion of leukocytes to the endothelium. The oxidation of LDL by 
ROS has several effects on endothelial function and integrity. In addition to the function 
of the stimulation of VCAM-1 and the adhesion of leukocytes to the endothelial surface, 
oxidized LDL induces endothelial cell toxicity, inactivates NO and impairs receptor-
induced endothelial NO production (104). Another indirect mechanism involves 
angiotensin II-activated NADPH oxidase which produces superoxide that can also induce 
expression of these adhesion molecules.  A third indirect mechanism is hyperglycemia.  
Increased glucose levels lead to glycation of lipids and proteins, which in turn produces 
advanced glycation end products (AGEs).  Interaction of AGEs with their receptors 






ROS and EPC function 
 Endothelial progenitor cells function in angiogenesis and re-endothelialization.  In 
these roles, EPCs home to areas of injury that have high levels of associated oxidative 
stress. Progenitor and stem cells characteristically have a large antioxidant capacity.  In 
EPCs, it is believed that this higher antioxidant capacity helps to maintain a self-renewing 
state and afford them with defenses for the environments to which they are targeted.  
Dernbach, et al (25) first reported heightened gene expression of antioxidant enzymes 
such as catalase, glutathione peroxidase and manganese superoxide dismutase (MnSOD) 
in EPCs compared to HUVECs.  Further, inhibition of any one of these enzymes alone 
was not enough to increase ROS in EPCs as the inhibition had to be combined to 
decrease EPC function.  The same year, He, et al (49) found that EPCs cultured from 
humans had 3-4-fold greater expression and activity of manganese superoxide dismutase 
compared to HUVECs or human coronary artery endothelial cells, when exposed to 
oxidative stress, although copper zinc superoxide dismutase (CuZnSOD) and catalase  
were not different. 
 Since these reports, oxidative stress has been implicated in decreases in EPC 
function and the effects of certain medications on EPCs have been related to oxidative 
stress.  Galasso, et al (36) found that GPX-1 deficient mice had decreased angiogenesis, 
decreased EPC function, and increased sensitivity to H2O2 to induce EPC apoptosis.    
More recently, Ingram, et al (66) also reported that oxidant treatment decreased the 
clonogenic capacity, increased apoptosis, and decreased the tube-forming capacity of 
EPCs in culture.  This effect was mirrored by activation of the stress-induced kinase 




dysfunction is telomere-associated senescence.  Imanishi et al (62) showed that EPCs 
cultured with the highly atherogenic oxidized LDL had increased EPC senescence, 
decreased proliferation and network formation, and decreased telomerase activity.  
Indeed, in mature endothelial cells, antioxidants have been shown to decrease the export 
of telomerase reverse transcriptase (TERT) from the nucleus, thereby preserving DNA 
telomere integrity (42).  In EPCs, human TERT gene transfer enhanced postnatal 
neovascularization of an ischemic limb (87).  In another study, oxidized LDL decreased 
EPC function, which was paralleled by decreased Akt phosphorylation and eNOS protein 
expression (82).  Therefore, the mechanism of oxidative stress EPC dysfunction has yet 
to be clarified. 
 Oxidative stress has been implicated in diabetes-related EPC dysfunction (117) 
with decreased proliferation, adhesion and tube formation.  Thum, et al (119) recently 
reported that EPCs from diabetic patients produced large amounts of superoxide anion 
and had lower migratory capacity.  Further, this effect appeared to be mediated by eNOS 
uncoupling.  However, in another recent study, hyperglycemia was shown to decrease 
EPC function, but was related to NO rather than oxidative stress (19).  Therefore, the role 
of oxidative stress on EPCs in diabetes-related vascular dysfunction is not clear. 
 
Endothelial Progenitor Cells and Physical Activity 
 Endothelial progenitor cells are released from the bone marrow by several stimuli.  
In 2004, the first evidence was published that exercise was another stimulus that 
increased the number of circulating EPCs.  There are data regarding the response to both 




CVD or CVD risk factors.  Although the mechanisms are not clear how exercise 
increases EPCs, there are several hypotheses based on what is known about EPCs.  These 




 The effect of an acute bout of exercise on EPCs was investigated in 2004 in 22 
middle-aged volunteers with various CVD risk factors.  Rehman, et al (95) found that 
EPCs (AC133+/VE-Cadherin+) increased nearly 4-fold compared to baseline values when 
measured 5-10 minutes following exhaustive treadmill or bicycle exercise.  In this study, 
investigators measured another EPC-related cell population; cells that were positive for 
AC133 and negative for VE Cadherin, which are early progenitors.  This population of 
cells increased 40%.  These results together show a shift toward VE-cadherin positive 
cells with an acute bout of exercise.  This group also did not find an increase in G-CSF or 
GM-CSF, two factors known to be powerful stimulants of EPC release.  Therefore, other 
factors associated with exercise, such as VEGF or eNOS, are likely to be the stimulus of 
release in response to an acute bout of exercise.  
 In a study on the effect of an acute bout of maximal exercise in patients with 
CAD, Adams, et al (1) tested subjects with 1) CAD with exercise-induced ischemia, 2) 
asymptomatic patients with no exercise-induced ischemia, and 3) healthy age-matched 
controls. Researchers collected samples prior to and 2, 4, 6, 8, 24, and 48 hours following 
the acute exercise test.  They found that EPC number in response to acute maximal 




maximally 48-hours following exercise, 3.1 ± 0.6-fold via FACS analysis and 3.3 ± 0.5-
fold via cell culture assay.  However, CAD patients without exercise-induced myocardial 
ischemia and normal subjects in this study did not display any significant increase in 
EPCs.  Plasma VEGF levels were increased in the patient group with exercise-induced 
ischemia but not in the other 2 groups.  Plasma G-CSF and TNF-α levels were not 
elevated in any group.  Since patients with exercise-induced ischemia were the only 
group to show a change in EPCs and VEGF in response to the exercise stimulus, it 
appears that EPCs were increased in this group as a response to ischemia and VEGF. 
 The other study that investigated EPC response to an acute bout of exercise was 
performed in healthy subjects to assess the link between extent of physical exercise and 
changes in EPCs (77). In the prior two studies, the stimulus was a maximal exercise test, 
which although it may be at a higher intensity, typically lasts only about 10 minutes.  In 
this study, subjects performed 3 exercise tests: 1) intensive running for 30 minutes at ~ 
82% VO2max, 2) moderate running for 30 min at ~68% VO2max and 3) short term running 
for 10 minutes at ~68% VO2max.  Samples were drawn before and 10 minutes following 
exercise and in a subset of the participants 10min, 30min, 2h, 6h, and 24h following the 
exercise session.  In addition, three cell populations were evaluated, including 
CD34+/KDR+, CD34+/CD133+, and CD34+/CD117+ cells. Migratory capacity and colony-
forming capacity were also measured.  Researchers found that moderate (~68% VO2max) 
and intensive (~82% VO2max) running for 30 minutes increased all of the cell populations 
significantly but moderate, short term running (10 minutes) did not significantly increase 
EPC number following exercise.  In addition, plasma VEGF level did not change with 




between 30 minutes and 2 hours.  Analysis of EPC function found that intensive running 
increased EPC migration and colony-forming units as soon as 10 minutes following 
exercise. EPC migration remained significantly elevated up to 30 minutes after exercise 
and then decreased between 2 and 24 hours after the exercise.  Colony forming units 
remained significantly elevated up to 6 hours following exercise.  The number of colony 
forming units reflects the proliferative potential of EPC and this remained elevated 
following exercise longer than EPC number, which may indicate improved endothelial 
regeneration and maintenance induced by exercise. 
 In comparing the studies by Adams and Laufs, they present different findings 
with EPC number and exercise.  Adams, et al (1) found that EPC number in response to 
acute maximal bicycle exercise in CAD patients with exercise-induced myocardial 
ischemia increased 3.1 ± 0.6-fold (FACS analysis) and 3.3 ± 0.5-fold (cell culture 
analysis) 48-hours following exercise.  However, in the same study, CAD patients 
without exercise-induced myocardial ischemia and normal subjects did not display a 
significant increase in EPCs.  Comparing these results to those of Laufs, et al (77), it is 
possible that Adams et al (1) did not detect an increase in EPCs in the other two patient 
groups because the sampling window was too large.  Laufs et al (77) found a significant 
increase in EPC number 30 and 60 minutes following the bout of exercise whereas 
Adams, et al (1) took the first sample at 2 hours following exercise.  This however, does 
not rule out the possibility that a different response and time course of EPC release may 
be present in patients with exercise-induced ischemia.   
 There are other more recent studies highlighting the EPC response to acute 




acute treadmill exercise in young and older healthy participants, and patients with 
peripheral artery disease (PAD) and that the changes in EPCs were more similar between 
the young and patients with PAD.  Yang, et al (142) found that EPCs increased following  
Bruce treadmill testing in healthy males and that plasma nitric oxide (NO) increased in 
parallel but there was no change in plasma VEGF or CM-CSF.  Van Craenenbroeck et al 
(125) reported this year that CD34+/KDR+ EPCs, measured by two separate techniques, 
increased following symptom-limited cardiopulmonary bicycle exercise testing.  
Opposite to Yang’s data, this group reported no change in plasma NO and a trend for an 
increase in VEGF.  They also did not find differences in EPC-CFU with acute exercise.  
In opposition to these studies, Thijssen, et al (118) did not find a change in CD34+/KDR+ 
cells following acute maximal cycle exercise in either young or older sedentary men.  
This group utilized magnetic microbeads to quantify EPC number, which may have 
accounted for differences between this study and the others. 
 Overall, it appears that an acute bout of exercise has the capacity to increase EPC 
number in patients with CAD, individuals with various CVD risk factors, and healthy 
subjects.  Data on EPC function are equivocal.  These studies on acute exercise also give 
some insight to the time course of release, with an initial rise in EPC number from 30 min 
to 2h following exercise, an increase in EPC migration at 30 min with a subsequent 
decrease, and an increase in CFUs that lasts for 6 hr following exercise.  This effect is 
similar to that seen in the Rehman study in which EPC number increased following 
exercise in the proliferative type and only moderately in early EPCs.  This indicates that 
an initial increase in EPCs appears to be followed by a more sustained increase in 




addition, VEGF and NO have been implicated as substances that increase EPC 
mobilization from the bone marrow; however, it is still not clear how and whether these 
factors function with acute exercise.  It is possible that healthy and diseased populations 
may have different stimuli for EPC release, proliferation, and/or function as well as 
different time-courses for release.  The largest limitation in comparing the response to 
acute exercise is that the exercise stimulus varies between studies; however, the lack of a 
uniform definition of EPCs and methodology to quantify them also likely leads to 
problems drawing conclusions from this body of data. 
 
Exercise training 
 There have been a few studies published regarding the effect of exercise training 
on EPCs.  In 2004, Laufs, et al (78) measured EPCs in mice and patients with stable 
CAD.  Mice engaged in 3 weeks of voluntary wheel running and humans underwent a 4 
week training program of bicycle ergometer endurance exercise (60-80% peak VO2), 
strength exercises, and walking.  In mice, EPC number was measured 1, 7, 14 and 28 
days following the start of wheel running exercise. EPC number was not significantly 
increased after only one day of wheel running, however, EPC number was significantly 
increased in the blood, bone marrow and spleen of mice after 7 days of exercise, which 
persisted for the 28 days of the training program.  The up regulation of EPCs was 
accompanied by an increase in NO and VEGF but not SDF-1.  EPC apoptosis was also 
found to be lower in the exercise group versus the control group after 28 days of exercise.  
A subgroup of mice underwent vascular injury.  The exercising mice had decreased 




number increased 78 ± 34% compared to before the 4 week training program.  EPC 
apoptosis was also found to decrease 41 ± 11% after training.    
  In another study investigating EPCs and exercise training, Steiner, et al (111) 
utilized a 12 week exercise training program in patients with asymptomatic coronary 
artery disease (CAD) and/or cardiovascular disease risk factors.  Samples were collected 
before and at least 24-hours after the last training session.  Endothelial-dependent dilation 
was measured in subjects.  Results showed a 2.9 ± 0.4-fold increase in circulating EPCs 
in the exercise group. This increase was correlated with an increase in flow-mediated 
dilation and NO synthesis.  These results show exercise training to be beneficial to 
improve endothelial function and EPC number in patients with CAD and support the data 
found by Laufs, et al (78) mentioned above.  
 In another training study, Sandri, et al (98) analyzed the responses of circulating 
progenitor cell (CD34+/KDR+) number and function in three patient groups; 1) those with 
ischemic PAOD, 2) patients with PAOD who had revascularization surgery and 
performed non-ischemic training, and 3) patients with some disease who performed sub-
ischemic ergometer training.  Training occurred for 4 weeks and consisted of several 
bouts of exercise/ day (6) at 3.5 km/h in the first two groups and 6 times per day for 10 
minutes at 70% max HR for the sub-ischemic group.  Researchers found that the group 
that performed sub-ischemic exercise training was the only group to increase CPC 
number following training.  Increases in CPC function (incorporation into endothelial 
networks) was increased in all three groups accompanied by an increase in the CXCR4, 
the receptor of SDF-1 which has been found to be important in EPC homing.  Plasma 




groups.  Therefore, although EPC function, measured via incorporation of cells into 
endothelial networks, was increased in all three groups with exercise training, only the 
ischemic exercise group appeared to increase VEGF, which may have stimulated the 
increase in CPC numbers.  Thijssen et al (118) reported no change in CD34+/KDR+ cells 
in healthy young and older participants following 8 weeks of cycle exercise training for 
20  minutes 3 times per week at 65% of heart rate reserve.  Therefore, exercise training 
may not increase EPC number in healthy individuals. 
 Hoetzer, et al (54) utilized assays for clonogenic and migratory capacity to assess 
EPC function in middle-aged and older men before and after 3 months of home-based 
exercise training.  At baseline, the clonogenic capacity in these two groups was lower 
than a group of young sedentary individuals. Migratory capacity was lower in older 
compared to younger men.  Both colony-forming and migratory capacity increased in 
middle-aged and older men after the training program. 
 Overall, exercise training appears to increase resting EPC number in mice and 
patients with CAD or CAD risk factors, and patients with PAOD, however it is not clear 
whether training increases EPC number in healthy individuals.  The EPC increase in 
patients was accompanied by an increase in endothelial function measured by flow-
mediated dilation (FMD) and NO.  As in the studies on acute exercise, VEGF appeared to 
increase with exercise training in patients with ischemic disease, although, VEGF 
increased in mice in the Laufs, et al (2004) study.  There does exist the possibility that 
there are two different mechanisms of action between the ischemic patient group and 
healthy subjects.  Exercise training also appears to increase EPC clonogenic capacity, 




SDF-1, which has been implicated in EPC release.  Interestingly, none of the exercise 
training studies or acute exercise studies showed an increase in SDF-1.  Therefore, the 
receptor may work in homing without changes in SDF-1 concentration but the 


























Limitations of the Study 
1) One of the limitations to the present study was the small sample size.  The sample 
size for this study was calculated based on many factors that were unknown at the 
time the study was designed.  Given the large amount of variability in many of the 
EPC measures, the inclusion of more subjects may have revealed more significant 
relationships, differences and effects. 
 
2) We proposed to match our research groups by age and BMI, which we performed 
successfully.  Despite our efforts, other factors differed between the groups other than 
VO2max and training status.  We did not observe any direct relationship between these 
factors and EPCs specifically; however, we can not disregard the possibility that 
some of these factors may have influenced the results of the present study. 
 
3) There is evidence that EPCs may be influenced by gender (53). Since we only used 
men in the present study, we can only relate our results to this specific population.   
 
4) The interpretation of our data should be confined to our definitions of EPC number 
and clonogenic capacity.  We defined EPCs with commonly accepted markers (CD34 
and KDR), and used a commercially available kit for EPC clonogenic capacity for 
which endothelial cell lineage has been verified (51).    The field of EPC research is 




consistent methods to quantify them or evaluate their functional characteristics.   We 
can not ignore the possibility that we may have seen different results if we defined 
EPCs with different cell markers or cultured EPCs with a different method. 
 
5) We can not eliminate the possibility that the repeated measures results following 
the 10-day training cessation were an effect of regression to the mean.  To evaluate 
whether the changes observed following the training cessation were an actual effect, 
the study design would have to have included repeated measures in the control group 



















Definition of Terms 
 
Angiogenesis: The growth of new blood vessels from pre-existing vessels. 
Antioxidant: A molecule that can prevent the oxidation of other molecules, thereby 
decreasing free radicals that lead to cellular damage. 
Atherosclerosis: The development of plaque-like lesions on the interior of the vessel 
wall via a cascade that begins with damage to the endothelial layer, subsequent 
infiltration of monocytes and macrophages and inflammatory response.  
Bioavailability: The amount of substance or drug that is present in a usable, bioactive 
form at the site of action.  Bioavailability is dependent upon the rate of production and 
degradation. 
CD34: A cell surface glycoprotein that is found on cells from the umbilical cord and 
bone marrow.  They are pluripotent hematopoietic progenitors. 
Endothelial-dependent dilation: The relaxation of the smooth muscle layer of a blood 
vessel due to the production of nitric oxide from the endothelial layer. 
Endothelial function: the capacity of the endothelium to regulate vascular tone, immune 
cell filtration, and angiogenesis. Endothelial dysfunction is the loss of this capacity and is 
an early hallmark of cardiovascular disease.  In vascular biology, endothelial function 





Kinase insert domain receptor (KDR, VEGFR-2, CD309): A tyrosine kinase receptor 
found mainly on vascular endothelial cells that serves as the receptor for vascular 
endothelial growth factor (VEGF).  
Maximal oxygen uptake (VO2max):  An indicator of cardiorespiratory fitness, the 
maximum capacity of an individual's body to transport and utilize oxygen during 
incremental exercise. 
Monoclonal antibody (mAb): Monospecific antibodies that are identical because they 
are produced by one type of immune cell that are all clones of a single parent cell. 
Nitric oxide (NO): The primary vasodilator in vascular beds.  It is a transient signal 
molecule produced from L-arginine by endothelial nitric oxide synthase (eNOS). 
Oxidative stress: The state of imbalance between the production of reactive oxygen and 
a biological system's ability to detoxify the reactive intermediates or easily repair the 
resulting damage. 
Oxidized low-density lipoprotein (OxLDL): the oxidative modification of LDL that is 
involved in the development of atherosclerotic lesions via uptake by scavenger receptors 
and foam cell formation. 
Reactive hyperemia: increase in blood flow following a transient period of ischemia. 
Vasculogenesis: is the process of blood vessel formation occurring by a de novo 
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